var title_f29_6_29792="Fatty cast";
var content_f29_6_29792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fatty cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing a fatty cast. The fat droplets (or globules) can be distinguished from red cells (which also have a round appearance) by their variable size (from much smaller to much larger than a red cell), dark outline, and \"Maltese cross\" appearance under polzarized light.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29792=[""].join("\n");
var outline_f29_6_29792=null;
var title_f29_6_29793="Dermatomyositis - heliotrope eruption";
var content_f29_6_29793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heliotrope eruption in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDy60DHBPStWLAUZ5A6iqFmoYLgir6dccYH61wNHqQLsLE4Xqeuavw4BznAqjbgebgkirwPoQ1K2upumWYzuwF/OrBQhQOoPfFVrZxu45I71fKsUHp6Cm30HfUW3Ql1VaviMZGevpUdrH0faBjirQ28ll/Wi6JlIfECqZTJxUgiLHOM+tSQKowv8J/Sp1XPByuO9XuY3I0wFwcD+lLnAB5FOKc4bOO/rSSHEgVcHPan5C8hfM+XBGc9qkjwDz1FJxG4BAPH41KNuc44qkgvoIx4JxgHvU6N8gz1PeoGdTle57elTqdgwcEiqSE3oS5JflugqRSp4zyRkn0qkzlvugcdT3zU8BBO7kk8kGqGloXSSUI7jr9KjZi4CkcDvTo/mBPAyKbgFRgHOOlOwloKhwDtbd2FSMx24GcjioogFTA/AVI+Cq7Tgk80WuDYbi/qM96nTb1bJCjGSapxvk4BAxxj2qzHtMBLA4I2rz396EhskiySFfPzcnH6VOrnDBvnIwDzUSgDYXOMrwT61ZRW8vPHPUGrSZLY3IxkrubPFSSLtCq2d2fXp6UhwxBXdkimnIBMh4HzAAVViBMYdWYd+cGrBbKgAAZzgDvVSY7UOcDIyFHPH1qS3m5XbncBz7iklZ2CS6lsDaWDDbtGKib7u45KqePY0oO4E44IzmnSqCpQEsMg8dKqxKZW2kZLDGO/c1DHNzjAxnPSppjnIOTnJBqieDxkge/T3qJG0dVqW9wkbAOQfbFMm+ZCAeBUMTt/eIPvTVl3sO2e3pUAlYoyQj7Sh2gnOc46Vow9BuPtmmKy7z6H9KnG0qc846etO1y51G0hD8qk5JHSo5EywIbIPWoWk2kjHHpUgcq+cZGOx6UEWsOQbgcjgdKcUypJOMc01BtYg85HWnBtuNx59ulTYlsawHDDrioOrEuDVo885B9qjdBg5yPQ0C5rkG0lmzx6VE2d239KtNgYYHnHNV2BZiR6cGlfuCKs8ZwWJ6etZkpENyW/hf7wHrW0wLAqwxx1rNu7fOf5DvUyV0VF23KshULsXG0nK/4VnOqq5H3c9B71dABYxSZU9qY8QGMrk9652u5urIiQuUyM5/rTL9BNbhxkSDnimtuikV9xZc8jFWONm7jA5x61lLVGctGmVtOmeS3aPIO4bce4qC+Qy2jjuo3fiKH/ANEvUwcQyZwfepZRtkYHOxuR71PUzfc8zsk+XjtVqM8kfKKrWox0bg+9T7gTjrz1rY2grmjbEr8oINW1fDBRgcfiap2yYI+YVeiX5sgcdzVXsW3ctQqdwZjjPOBWjEuQOao2wG8ZBPPetWPIBwpAxnNFxsuxhTGBjkU5QGIGeFNVFuBtKAcnvUguY4gAzqPp3pPUzZqoVIJJ5+lKzqDjJIPpWWt2XJCj5M4A9ae8zbiq8DHQDFUrk2NFZADhhyecGgupbplu1ZCNEpAZ1L+gO41Ml0rsSDtUHAZjVoVtS91JIIJHf0qbeETc2WPTjrWI96BlQS3pntSvekLhmUkDhU5rSI2afmqACQc561ILgEHPTvWKl8zSECQKh9KlN2qtwzEepFUrDaRsRtubIxjPQ1ZhcE56DoTXPx3AbozMfQf1rTt5A21nRST2zTQNGqHzJncPZakWYIDng4xgd6oxFF2sBg+9TCaMqoZsZ/OrSsZ2LKkMfl7DIHpTmYup2EEgVWD5+7kADAz6VIW25AIIxzigVw6MpCkVICDhT0ODz61Cr9Av3jUyYZgCQo/rSWhV2WlHmOF5Py81bQgITt4PABqpZuEZtwyHG0DPQ+tWo5QHVc4GeT61pFaETetiaJgAMLtPIIPpSNGzg7EPQkDpgUxCu5yOOwyeppWz5QBJZSMepNMzu9yqTmNlYgNtPOOwpbYBoxkspzgmknyjIG5BG3PpS2wMWMdWJOCTge9T1LctNS+G2qAATwCAf5UZAIG7a2c1AMs5LH5ewXnnvUSkqoJwWLdT0xWhFhs7tvPUEZwfbNQSOpGGHI6HPWnyOzAYbI6Y7dahlQuMqw3ZqJGqYqk5yoHApy7MA4JB9aZEcg7hg9xT94Bw5AA9eKmxLmV2BEmF4FTA5H3sEc8dqjnliTdkgH9ariYMuVIx6g4pWDmuSu3zEk7c96VXAG4kAfWqct3Eow3Dduc1UnuiFVkVm/2lIIP4Uhts3EuU6gjd2zSNPlSVPI/vdDXLPqSBSHkbzP7oHT9Kamr7SFMm36rx+NS3poLlZ1TTAhSyqG9QaHnTG1iT9a5oapASVM8LEdgDQupJkCO5X0wRkVN2ibHSCcbhimMyqOOufpXPf2iwdlfdx3XODT/t824FJCRj7p5xU86ZWuzN3zFKkAgn0PFQSMSSBjPpWaLmd42LeUxPQH5aqyXzoT8jqw7Zo50OJduoPO5wARyKrB8r5bkgiiPUd6gMrc9yc4qOUxFl3IRnoyt1qJWeqLWujIrmIhWOSQRkH1qvBKyAhQCQp4arwljKbQWx74NUZ02tvX17Vzy7lJXVmRSqlwiox2jduRj/AAtU94CkEchHoCaqNuLnoI25B9DVqGTzraSCQ8479qyfcmSseYwcDG0HPSrOOB061WT5VAXBz3qVWJKqBk1sax0RpQrhce1WU3cfe9KoxykIBg5Hfp+tPM07AsGEUY/iI/xqmxppG3EZEUM5CsOAD6VYaUsP3kjsOu0HArmU1K1tmw0ks8npHzn8aifUp7mT9wropPcYH/16WrJczpC8sjbd4igB5IPX6Usf2cMdqtn1dq506i8JCyh5X9Bzij7beyAYjKIegIwMfSrUEiOY63zQM7MBT6NgfWgyugJijjc9GLMTiubiduMMQx/AVYZ25e6uJgg6BWGP0qkg5jTutQaJh5o+TuqMBiq6asuWAURhem47sVhy6jaAHy1yP4iSazZtSh3HA8z/AIBwKbvfQXMjp31mMAhCkh/iBOKfbahEzYeYwxnnCDP41ySXobkQqBngdKV7hDkYIJH3WH8iKdmRzHawywFg0N2hQ5yJAeD+NPGpwRJlnLsCfl3YBHsMVwy3XRUZgRzsf1q7HepvETA59gVH61Sb6BzM7CDWIXYjGxu2W4xVq21OEsAzAehU5ri1uUTDmQgf7Q4PtVpLrDZieME8jbxV36stTO/t7kOC0U4OffNW4pgfvBT6Fc81wC3UrAOsIb/aB/pV23vJFKb2lC9MjvVcwzvldAoPOPY9KBcqFOJFJI6GuetrgSIAJZlx7VagcSDB+f8AnTuJRtua/wBp3BeeV5FWI5QVDEAc5xWQrhWx0q5HPlVCgiqKlpsaqSZKbcAjPOf0qwnJXhsjk5PSs6GUM+7B+vpVyM7iFB+cgZJ7H/CmuxEkXBLglT87ZwCBxn1qaNkKsynYRzu9aoh2L5wwJODjvxVxCAEz8+BjDcU7mUlYqPh/NypbJ7U6xO1AwG8LlSDRIcKAr7XJOVXr+NRW8h8uRHyvPDDvU9R7otbmViFKgH07VDI7KQAcjOT7VFPKVfllIJyCvSmuw+8Cen61V7jSsI7ktkEYzmmlyuTjNVXkO8AAe9KXUktuz7HtS3KkStMUXdjDY9arz3chjJUIi99/NUby83OEQgRjnLHGT/gKzL1xKu4l2THLMSqn6CkyeXuT3GpFFA+0x7Ox7fhmqEmpTSfLF8+48FM4/Gs26vVBdYpEGBltvp7mse4vjNnazmFeNwblj7e3uahjRuvqRV2Qy75O4j6VWudVaFBhniHX5sFj9awkvGtwXiVIecAu2S30H9aopNK0rTyMcFurclj6YqdGS7mzca1IyqhZgx/vDk/Rf8aha/kdW86J9v0xzWPvy2QwHPJPNTSTKpO6XJHGQSx/AelJwuLmsaKzWoRWMZ3DqGJUflmpRdBiAkaDccfLmufT96dsW9vY8496uHfwqMoIHILgA/U1Hs2h85uidwqqkewA/wALk/mSaclzdEsvnFFHOeSfzrnVuDCcqGkY8HHA/wAakt7iUk7IGRs8lCf60nCSCMkzoYry6ikwJwob+InOfwq8bydwPN8pgB95SQf0rlHUysPMlG5h/wAtACF/GpbePyt3l3LOfRGOPripZa8jqEvFVm2yT5HUKuaZLqK5BM0gfHCsgWsFppN2JZVJ94yD+hqU+WI9yXLIw55bI/Wpt2H6m/a3bkfvFU46sPl/SrPnxupKsQvUZFcpFevuJ+0Qyn/bT+oq9FqE5TCCNT6K3H5VDbLTsa7FT8jMArDj2qNnaGUSZyR8r+49arJcNIQsigv2PYH1p8soWcgkOkgyV9PWs5R0uDsziAAo5wQBVVrpkU7FLE/dHemzznJGCT35ojbYuQFZz1I6fnVhJ9EPS4m3Azuyt1HqKexic5cyyv6sTgU1niwBJJ8391F/rSPOxysaMqdCxGSaqwtB5uYoAViQFj1A6n60FpZ8mecRKR9wHHFVczLxHEyDu2OTUscCyE5kcMeu5ck1aiGpOkqgbFnQL/sKTSl9uGDNKB/CxNSJCcbUkBX3AqxHGIzt2Ag+lWojtcqi7vSwWCEQIR1K5P5mofsd/PIXkdzjnJ5roYIoplAdmjwOuOM1YtrNOpL7j0ZTx+VX7N9R+zTOXTSZGy0jZ46YpRpixpyj+x7D611iWjIzZ+YdOnWpPsiyR8E4Axgf1q4010B0lbY4qaxKnGzBHXaapuhtpgcM2e7L0ruLjTCSBGBkdMVmXGn4YmQMr46qOaOWxDonOECV8lVYAD5TwakVxHvRvMAH3WJ5WtM2KuNxB3Z4dO31FNaykj+Yjcn94c5pbEezZQjuHEbfLuXOCFHOPWpra524VyrEnI7E0klvhlYrg+qnFI0W0NlSVPPHUUmWoNGhHepEVKI8b9G+bg/h2rTXUEI2EyIG4yRkCsKNN3KlZUxwM8ir8MeEVo87ByAp5H4HrVXBRZ0Nvf7dpLGPsVPI/wCAkVtWl1FM/lyFd55z03D1+tcpZSRS7oiFD45Xsw9h/nFaFvcNG/lTDfs5Vgctj196eqHZs6hWKuAXDg/dJ6j61YgcM5WQ4rMhMTgAjkjknv8ASrKSqgXPPYEnJFUXFXVmbMDkMqryMYINXbeQmQZ+XjPtWTaMxORzjuetacA/ebjyo6j1oTBo0kbGGWQbgThfWrCRoVUyKRnrnkg9yPaq0IbCZKByeP8A65q1G0XmnKNwuAWOfrirvdnPLyIHUJIPK9cEkfyqK2ALTxHJHX3q5IVeVQ+Ax+6QOB+FUGUmd8fKzcqw4PuKm3US1Q9xgbDg7eg9ao3EhMZ8vGfTvVyZhtAxhh/F61jXdwVO11AYZ/H8ad0jSmrjWuMgkEE9OlVrucKhDZ2Yyaill+U7cAkYNULseYVhUkouN3OOB296DS2okkwSIzSlct8w3dF9BjvWRLcvfea80uY06B+FX/6/t+dWL1jNLtLbUXqqjn6Z9axL2d3cQ2kCgoPkyflXn73ufc0k7ehnJdEQXkrztJG+5bVTzgfNI3qT3rPuZt8ywqm3acJGpyB/j9auz2syKV8z98cY3HJX19h/OoYo/LiKxqHTgyP3J/z2qHqwUSuSoDbyY1b5SI/nkf1yf6CmyuAQvlskRH3Mgt+OK0ltJGjwVEcQ53FsH8ajj05Ika4kUeUBkGQ4JPso5p+QSiYzFioDFiSflBIH6URpOD8z7F6EgZJrorXRWYrNcwvGDyEIAGKu/YC+0eUAmPlQNgAU7N6kqnc5eK2lJ228UsjEZPYVoadod1I25YxvHJyvyiuptbRljWPaiR9fLUYB9ye9bNtbKkOz5gP7vQU4x6jdOxy39k/LseZ2kxyRgH9OlI2mbQS8gjB/4ExFdYsWeFXYDgH3qBovs7kRImSctJiraSHGn0OUksQiDeJGVfUYBpq6dIQCmYQ3fPP5V0MsUYf5/wB4zc8jOP8ACoLhHxhTuzztQ4P59qykl1NPZnOyaaVb95LKTngvJiopNIUK5cs4P95yMVsSRZ+ZdsTc8qNzH8ap/Z0klxM0jg9i2Kz5FuiXGxlRWkEe7y3Qk8EYJP51bisrYc4YSDpwRWlJbeWo+zxouB/CBUb3c3EbxAJ3JrKVOwh8G1XUSTyKc4/yauXqyeUjhgyr8pJxz+IrK86RX2iQlSOjj+tOWVn/ANUkW4AZGev9Kxemg/M5CNBI/wC8zjqc1K72cbAY3nptUkmqjyM+3CMEPU561Zg/dDMKsvvjAqkhosK0zLtgtVjT1K80wW0277rk5ySWA/lVi2mjYEyyhiO27mlUhiCSyg9s8mtEgSIxBIjDOWkzn75NTxwO5BKZP1zUsXlKWK9z2qzBJuzt/wDr1aRag2Pto0K7ZBggdMVLHAg5LMM8DilRSjKzcg/pVqIncTjK1SNowsJbxOj8vkdgVq+ysuclWPqOKLeBcEksp96sNGdnUccg02y1FXEjhQrhQxIPUnpVpIwqbsKD0yetMiHy5Lk57VKAQT0A+lO9irJkQQuCSOg6nrUb2quoMhG8DIq2EO0FgcY6CnhORnBxyOKdyGkjBfT4y7JIoznKkf41A1gQmUBY9Nn+BroZIQ4B9D6VE8bHLR7cemOtBLSZzC2ilmBXA6FWHKn2pTpy8lkBycFh2rfmtlOGPLDqBTHtyqfK3HpjNVZE2OYl04K25Adw7j0pYIQrcLyeoPA+orfeMb8sPl6dKqzRAZxyM0uWwuQqCFWO4oML0b+JfetCF1TDSxZOMbk6H3qqWA4cfLU0ZXy+cge1O9iXA1YyPNIByAcECrEYAc5yfbNZlqTvI5ww6jtV+PDYzkY4OKhsqKsbVm4VB1zjmteFyFwowD79KwbLKMo5OTWtaL5h2PnHotLmFJG5C+ANyggDAwcmrQX5W2LgDkB+uagtY8hcHaOlX0jOwojgqOMkVonc5J6EEm1ivmgBkA5B6GorlMyB9owBzjvVp4ywIbDfhgVTuyFbCKwA6H0pXsSvIqXBJVsEMOnNYV+pcMOWIrYuCS2S4/LrWZerksM/MaTkdEPdMKQsrKMYwcZNJM/zAY+Y/lVh1zkFc81TnClmycD0qkypO5VvZQsZjjQEEc/3V9/f6VRhQQklYy0p5GeGJ9W/wrS4B6k+lIQGfcelLcXJ3M1bFpf9aeSeccAVYWxyygAAIeAB0rSijyoznGOlWCo24X07DmqSHfsZf2GLPY+xpfIDPvlGXGNuRnHvWiEBOFj4/vd6ja3aTIkkxj+FTjP407jtcqxIbicqB53YK7VaitWQsWIT2z0HoKuWtphQrAIo7Y61fWz4B6D+8Oam/cOZRZThj+8D85I6dhUjRFdpBORxjsTV5LZUIfhivO8daYyEMSA6qfWqT0GpJsrl0JYgfiT1qJ41kwScE84p/l+WVjQbU5JPXFSY2xnBAJ6fLUsvRFC4hZec4bvgVSfbtznkDlc1sSKNhBDE+9Y9wiLOFJYqfQd6llRs9CncAMo2kg9wpx+tVmhg2OAvydweefer0ilBk4GO9U2QEFpBkHnjvSvcJRSM9kjDjA2oO6mo5LRJAW82THvWgxjYFQgH/AaqTruB2qpI69qTjc52uxA2YztaZnT0KZIqeOCKRcoFBI6KwU1GhZSN7LGB0w+f0qM/vJtzOpXodqYzmsZRRDZysnlowBJ3D8qsxAFSH6+gbioEtmVxsdj7sc1cSMIAGBz7VES7CxQxk/cGe/FSeSgI5Az70sR+bAJNIQQ2GwO1a2LURSrK3ynHrx1qeNjxjt6VV3bsYY8GrMRUPwSCfQcUjaKsXo5NwO8kjHar1mfkU/erLRvlwvBPpV21ZgASfwNO6NbaGwG2MMc561bU4GDgZ9KzY3Jb5OPTPT8qvodyLuXnue5q0QySMru5Ue2TUwCu3HQHOOtIkYLFlTHGDuPNP2krjBOOgB4rRWZDlqPYgj7jYzwOppH3DBwoHTFQlTnqIQe5yTTljLqOAXHVieCPUCnyCJQxU/O+Ce2Kjbah4HXjPr9aYIyzgpuIHGW/zxUm0lMNn/Ck1YkglwVBVSx9ewpq7dwySWPXjpU2QVOG5Wm7S27LDd7VcfMbehBLGGyARx69TVORFDdjxV6ZxlVfnHbHFVHAJIHH0qnESZnSgc7SOKbGRxgZzT7qJl5HHpiqwYq+W5/SspRtqUkmaEL7GG7vV+CQ7RjbknrWSsgYA5xjjNXLeQhlOQDnFYtlpHS2WXUA8Ad/Wtq0UoMqeKwtOcnlSeOM1vQyAMvzcH19aXmZT0Na1bdHgHBJ/KtGBX8sKVyPfjNZ0C8qN+0n0rVt416u7Ej9KqLOWokEqkkjGOPyqhdk4x8wx0PatGbKjO4hT6jNZ158y8sB3+U4qmyIoyp3IboDkVmXTDdu5GeK0LnlTnqOlZk7NjdggYzioub2M65JUdQKyp5vmx/D61bvHLZyPp7VlTPtAz3rSJrBEyb2I5xzViLqFxgHjNVY5SAB2P61ahLMT1I9a1SG/MuBwYyvJapEVzhn+Vj0yOKggbA5OG7ZqwsrBBuJXn6g1Rm12LIT5CQGBPpQIkbH3QwOck4NNEoxkE+/sackgyu5huxwxFYy5tkTsXYMBlJ6HoC1WMhTuIUjpnHU1nCQlwWVdnUs3VferNvNbnJZ9i9SwGfwx6mmoshslY/OAqHaOpPT8qSTYQTIo475qWJPNRf3pjViPnY5VV7kjriqsiNvkRZVKxg4fGOPaq5bbjU09BJEjIBDMGzySMVFNIVQbSAvTjnFPmbbhSPujG1Ryfcmo9i/KWIU9celJlpogml3Dqc1nzyEtnZ0OKtz7QeGY5OBxVYqrFWbAcdQtZ3NotLVFOcqyk4AGOoqg+5SdnIHTHWtaeJDyUA/rWdKm0kg8D06UrlKSK/mnk9PaqsoWZ+V5x0pTuLZccZzU8YAIxkg+tUtTKejIYIUVshVz64pqrulJM2MH+Hir+1Co6VXIUOQqBzUyRi9zkRFnHmdD3Jq0qkYxjHsaFVNpGM49aeIwo3AD8KxiXFDclMgDGe1RM3djtxUkkqluxNDICPrW3Q3sVsjk5JNTKzcGqxXax7c/nUy4PO7AHGaxZSepcjbcM9auwvsQHaT+FZ8MwXp34q5HLwDjPbrRctSZs2cnGNy59x0q9EN5+Xfj9Ky7SXnsRjrWnBMwUFCTzVoybZrQQyAFyVBxx71ItuxQSnpwQxGPqKoxTszDefwrRtpd3lhmXg7W+n9a2grmcrrUSO3MymRIJ2AXzHRB0GeW+lOuLYj5o0Uxkja2BtK+p7/AF9K0I7mCBX/ANJdXVCseT1U9lPY45weO1Zkl5Cyy/6Ed7JhF3nEbf3vcn0PFdXs7IyjKTfkMn/1zKyxsclQIzkN9D3qGbAJIj+XrtVs44qBJJ8KYgUOcgjhkx3B7U1/tEcQjGSpOwZOBg84/rWfKatWEkmJBKAjJzjGaZ5g2bmwgwOSfXvTbl5QBvZFAXGAc4HvVORgYxlgzn9KXLZjumiXzBLnGSST+NREEEgFdtOgHyqN/wAx54qQxrn7mSP4qNRKajoVbna+ArE49utZNyWV8SKfatx9inBwP5VnXKJJuGOB096VTUITVypDNg8NmtmzlDLyoz6msYoY3Ude1X7MlTg4ytcskdHxKx1emOBgnoa6C1KvgFcY6DFcxpkgCgsMZ5xXRWcjMw3HC9RU3ZlJM3YE+6wUfKOtaVu6jqcZqjasfLGSGFXFdtwG0eh9qE2jnlG5LJJuU8HHesy92nG3j2q5K52ZA3EGs+9GfvdewFNu5MY2Mq6V888+9Zt05SNt3fuK05yWBC4rBvnIbZJz3zTizZamfKdy5JzmsmcDdkHoa0LiQbcDr6jv+FUQBIScHj2reBeqFgQZy2cVpQBdvJxjjFUEwHUD5j1PtV9XyQgGD1GRW6dzKcmSKueR0qZgNnUHPGCKaAQgTjk55HIpzqdnXOfXsaTRF7g4yU8pQjnHAOVY+3oakiB3/OhU9Tu71RZkDbZJFUL0x1zVuFty7mYcEA5PUVL1Lt1Li7XA8zkeueanhgilfLSqg7kr/QVUjAyQA3y9M8VoWc5Ei+WxAyQpdQc56g0JGctNieO1kgCsUKBztG3HPHQfpUksSraGSVGLMwCdNp45z70kdy6Ry4chDw4HGPTFQNP5uAAQE+XrnjrVNIiPMxMHKqQVX24A9qrTBUyWaMDHQevuatyKzNnB8vsT1rOluI48qVAH0zXPJmsU2VppSxJ2kBRwSPlqGRz8rFwCe61KZoPMLkkt3XFV5SjsTHjPpUXNrNEc0rA/eGPU96zrmU7+uanuE2nJOMduhrPdsPnJ9hUuTeg01Ya2Tycc+lOiIPyt2FMU5k5Hbigghzt4q4kWu7FuLDDdngcYFIQAcjB9BimwSLtC5qcLk+30okyJKzscm43KBgH6Uwkr8pO78Kt7doPG1qiMQkOAQD61ijdRVym0eJAygZ6VYCMMDI+lOSFueMj2qSDLMflGe5Napml9CjdIw7H61EjcAHGa2biMuhA54rGkjMcmOBj9ayk9TK5NDwCcDJqRHZPlI69Kg3hcE8E+nenCVmPYCkaxehq2cm3KqQfqela1pMSCTnHauchmCHGOO49a0ra7BA5O3PftWkVoEkbyybzgMoHr/WrqAhAwGUHylwDgmsKGU53LjP5VoW9yxyWOSBlQTxXRCNtjJm4lwktq5dTuUgLt4VffPf6VSmvSiOkGVRhg7wCTz3rPa4Abk5yOmcZpk0u4rkY56npW3M9iVBLcuid5ZT9njwnO1PvY45pbqURwQxQOzxsFkaN1A2uD2/xrPW7FuNwQJk7lOe3TH07VE948000hKBGb7qrjr2FXHRa7g1d6ItpLLLI5cFFZfnAP3hUEiRCTOQdo4xnioWnGxiDgdMZ70qSYRVDBmYbfxzUPUnlZahVlJ8rDAcZPpVoxeXHsbg9+ep9BUdlJCCTI4VEzj/aNW4Z4pYwyjzH6IvTHuaqyiZOMpOxRv7bZCXbCIOgJ5NZioGXIBC+ma6K4snlTMrFnPQ5qhPZ+WmSMY6H0rlqy1OilFRRhSrsjG7qOtTwMpxtIAx0pt4o2nnmol3KygYPc1i3c6Iq+p0mntwoPSunsOg6H8a5fT2DlTjOBXQae+2QnBx069Ki4NXOktSzLtIz24rTt0TBDZGOcCsyy+6Dt2nr1zWpbkHk5FNI55IfszHhsqPpWbejCnb06Zx1NbHJJCsx9ayrvLMw6gd8VMnbYhK7MGYEEhuOKw9QZg6hRkmuguWKMwIGM8Gue1CTbcAAEe4qos3hEypV556g1EgzkKDjvVpl3yFCckiq7jbjHbjHrXRF2G1cZACZyUGEHByavywsoUsylW6MoqtHAShyuFJ+93rSQG3ti7jfascFh/D+FdMLI5asX0K5l5BIO8HGT/OnsRISGY5JxwPypk21gwRlZcfKQeoqOUCNwVY7uCD7VTSZmlJMdbwICwlJK5AGRzmp1ifyi6DbGXwO4JHaoI3yQWOBknk45xUsU6CYnkR85x1/zmspI3V3qaMKFlxNIpdxyCvT8fWpBL9lUAODvAK4PQ/41R+1bYtjM21TnBPGe5pq3SBC4YEMCpA6kUeZPK+pqPeI8LJIQ6g4XeuGPvUE04kZnZsMONgH3Rj1qm8ylACV3Z6ntVaWUqMZBJzz1xQ7rcUVroWUvZE3EOCpHfJrLmvQrs0gwc9QDU5uQsXlRYVM5buTWdcShmOGAxyBisJRN6bs9RxuCcgyZB6Zpj3AQDoQefl4quSMMN3TpjpUSsAp3Hce1YtM3bTRZmuA2D2781DKyuMqfwqF8nrnB59cUi5AIJyKkwmkTwjec5PHTFTzKQu7HPpin2cGBuwSW6Y7VbeIIuCPSt47GKldlG1t5mETeW+2RyiNjhm7gVrTwiGQp5UsRUBXWTlt3f8Kljjg1CC2VppYHgTyioiZ0PJORjoeealvpFnuUMYk2xosQMowzBRjcfrSkgnq7nE+WzgHtUfkyIckfjirqZXtx2qxIF289KwWh1bGcqfLuYEetN4BJU8HtUzONx754ApmSMACqbLjSvqPAcp1GR2qjdWytgnjPr2q18zE5woHcVUvPPXcVfJOKVk9zGcddDMkjeNsck1G0ix/ebIqOeS4tnzJ+8j9APmFHnRTvG9vhlPDKetVFXZKlbcsJIdoJI9enNWoJMN85H0Hes6RXRwAeDyrH0/xp4kiyPKBZSOQ/r6itUrFqabsb8V0oUoWwB3NTJOSo+bp3Fc9DdFuGUcdMira3JwDjknOBWkRuxsrdISFxk9Me/rSnUvLYqyDnOMnpWS0rqinHfkVWkctJ5jPgZ6H+taJkOUepsSyksOcq3IP0qK3u23buNrZBYVizajEhKbiT1IAqpNfS+QHtiApP8XX3pttEe2gtLm+ZiQMN8uT170+XU44PlVxlR25yaxrBTdxtklyhG5ScAityz0aFn+UHbgEZ9PSovbUpVebRIoHWZplCWsLtg5yxxiui8OrfeY00uMscqAORVuw062jbmFSO+OcVt2SeXyIyij7tQ22zRpJXNCJl27nG0dSPQ1karcKM881emndn3Ag7etYN+4MjFR8nf2pTVlqRBamPeSbpRs4zx7UIApIJ6H1psmXYDjrnNTRIHcDAx6mud6bnTFGzprjeM8DFdRpIUkKRkVz2lwAuuARXVWELBl3HBI7VNinZI27ZTtXHAFaNr+8XKKWFUbb5cZ57Zq/asFZjuI4+70q9jlmm9SyBs3LsOCOtZd8cL8gOPTPetF2Y8AckeueKxp5lNyyo2ccGkEIN6mPKWkJ3cHNYmoffJIIxW7dD5mPOQelZV2m+QjJ5pXsb8pkFlDjnGfT1pAoMq7tpGeadcIyKGUHr0NQIV3HgVvF3IcXubAgWVkUEBRyfaqevToIZUiCkkc54FSWMp/iXNEsfmq8joGP8KnpXR00MYrWzOGXWHifZMGQIeCOhFatvqvnogDA7ed3X8q0r3TobiFlFuFb+9j7tc+fDZtzJNCxDHow6D8KlNlzstWaslzkhw24Pz9KV75UXLYA6/WuallvbB2LqsqKOB0NI2pwzoQxML/3X4rS6MeeN9zqJLkt3XrwSelPE3U5CfQVywvZQG8tww4OKet/M6noAP50mkaJ3OoN0APm2n19fpUIlKjG89M5btXOpfOD83T0FTtKWUbpBs4x7e1LcGjQmugqHbhj/AJ/WowdyjIJOPXpWd5vynBAIOR6Y9KVZmAHO0EYx6d6TiCZcmlXYp9OOOM1C0q9QTn0qhLK0jdS2OQR2pFYtIoBUk9cVlJa6FX01NNASAFJyat2tqW/iz7VUidYF3ysB7Hqfwqzb3ySNiNGIHcDGTWT0Mb32NuJdgCg9KmUKxwcEVTglZ1+YYx29a07GQpKrqFJHIDjI/KpUmL2dtjYt1d7K0S11GK2CIQYhIVOcn5uO5qhewy/a8S3AuHwMyB92R6ZrUtr9lUl4bYntthAqC7kFxM0kkaITgfKAox9BVt6GcVK9jz6L7x7mkuGLDjJzSJ0JIAHoTTgD1AyeuBWJ6UVqQCEsOoBHrVr7OuFJyx9KkhTIG5evX2q/bQhssw4quhpKVkZ89vgDHB6VCbdCACOfWta4VWXIOMdDVCWOaWPAaNV+nNS31ON3vcwtQji3FSOQM8GucubRiGeLbEB029TXbJaZZlIBUfxMOtZd/ZCONpAAzE4UDgZqlO25hNNnIi8vbPajFZEfJK9x6GohrbnarRYZh0A4robnTGj2NHCsgx0XrmsOS0xIiFB5zN8wI+4M962jUurHM+dbFsa3ApjUwtjGBnvUx1qIwLIkRB3bcr1zUOp6WsBWMMz7PmJxTYII/syFU+Yv0JrXnS0J5psfPrEgEhWIq4I5bniqTz3M0o3McPwcCtM2DR30ZuI3ZJQxTsSMfzrRl0pLtbd495XZtwg+6exNS6vUag3uc7Z2ExvktpS24gkeu3rWxpNo0yTIEypBGMclge3pXT2Wkrc2qiTEdxGcZ/iDDpz6GtLTdJMc7yrtj8wDcPQnjj6ipUmbRpop6PpCQxFpEzvHBxw3+FdJFaqdoijC7eM+oFOtowq4wODt/Cru1gwbORjsPzq49jo5bEDQeVEyLtDEbt3fFMe6AjVVyH6YBqzdRh4wVzvB+UDnPHSs7U4wpUhgGwCPYe9a2saJp7jJbhih8zHmZ61h3buTjd1P51YklY/PgDORjPFQxwh3BY5rlqSvoaxjZ3IbaFiWLjA7VPbxgyDHercgEUW0AZNFlFuk3DIA9BWEnYuJv6PBsG7nHvXSW4C85yT3rF0/bs4YCt+xIcbSv0oFLuW413FC3QVdiUsTk4GccHrUMEQQhRwD19auQ2i/fDHIOORkU0Q2rErK3lfIOQMZ9qx72Hy2bIALDNbMxlUcAFT1waoXLAJ13c0xQujn7wu2do6dc1mSgKFbIJ64reuVCZyPc1iXIKswK5WkbLVFS/ti0AkQcHnNYxhERVgpOeK6OJw8PldR29RWZexE5CjIByK0T7Eq60K8MnynbkY7GpY5SituJwep7iqoGGAB2561aiVRMhAyo6MT1+tdMJXMnFbliIMUDrjkY2n+tRtExYqEH17VeQ9DtBJ52ip1Qbh0Xj8qqSuZuZy0mmGSOfKgZzgHksa43VNOQ2023KNGolIPJHavV5Y98m7gD2rmtb00uZDjBZCFYjgH0NRqjCUEzzWytnMxBLBvL3D03Ypftc8QjOzeeARjHWurtdCljsBIqruQHMbcEsOv0+lZg00Wd5JJcCRLeS3DRu2dob0P1HSkqnc55RlHZmbDqsPzJJlHQ9COtPj1e0MbGSVcZ/iGKoTQK+ydWVwCwfb1QDoTV+Xw4JdPt3IdZ5UD428DirVRBz1L2IJNWtvJIjmBbOMA8mnw39tIqNJcKpxgqx/WsR9FmadAE3MwJGzOeKvWPh+4kRiE/eb9u0jio9omylKoi+dVsXg8vzgFBJGwElvfNJaXkk7MNOh+Xqxblh9BSW3hecyHIWN1badpzjPQ/StrRdClS982VG8+H5j5eBnPt7VM6qGud7jdFsZnl8wuZmOM785X8O1drZ6YiJuByTySe5pYLYb8yRbHA++OhrSiyMqPunpXO5nRGLitCvHbkZAA+lWba1YEkcEfnU8KESA5IFX4I9/UUkxOVmVrW3mcrGImYuSq5HUjrz7VPcxCOURG2MTrgMSxOTitoKPshkSKXekXkZC5RQTyfrisrUXZrwKI2QRqsYEg+bjuat7Dj7x5gc7vmA/HvU8MbMQcqB6elRbdxyQcDk1NCwVc/wAPvWZ2xLqKuVU/mKvxRgKQq4PfHOapWrCQ9iMc8dK07VQBndx0p7insVp4MgDbgj09KqtFhOMCtiZBjn61SnUeW3oR0HWkYrUoyDjORwOKoXVssgGOfmBOa0QpwMg011BPzZ57Yp6EyhYzZrc5wPlPXIqnHpcccsryIrF+QfUVvLCc/KOKk+ys/WhaPQlxRy91ZGSC5yu4kYXIqLS9BaSV3kBEfHyHua65bRQMkcj17Vct4AuAI/qT3prVk+zuY02lCZGYryozHn1Fa+n2KmMMu1cgFuKuJFuk3PnaBjgdqnCpsOSeCDx09hWiQKI2GzRVYhOhwTj86DGpGVH+2QParJzs3NtycZOe59vanbWY/MNxReR04z1/WtooajZ6lNUDAsBtPK8epFS7m2iQKwB7r64/+sandAZGVcBiFyM9O2aRdrSbJY3KbuChAPt/WtoJIpyuVWfyCTJypBTPv94fpXN3tw2GQYZieT7Vs6pNvXe7AyKu0D1H9TXPTbg4IGWPWsq1XSyN6EOrEjj3HIOF9DVuFTGPl5A5psMJbBPHPQVaIIwFBORXJzdTdkQ/e44qeP5RtJP4UwRGNQTjinRYd+pHHas93diWrN/R9z4HG36V00ciBlRRzjgjtXOaaTGMAAKepPWt2I5UHgkjAxVEyhdmiN0jAeYyrjt1rVtERYxg5PqTzWNZAyEE5U5/Otm3CjIC4FMyqaKw2VvLypyQfTtVCZSDu24UcjbzWjMpEROR9cVmXEm0YJIIHAzQKOq0MrUJSJOxB5NUWTzF9x/Kr15EZQ3ynHXJqjtIkyWyegPpSN42sVfLAOVGMioZI2C7cZzz9PerhLfMSeQOwpg/eJvXB9R6U72DXcx7iE7dy9uGxSxAsoDAknjcavlQpKnv97HSqgi3SHruxwfatqcrMmSumalrGjkgZDAdyOtWfKWRT2xwKigJMTBlX5cfP06VcO0kZALFsccCuxWaPPd0yuYAFyow5GMmq91Z+cNoI2twQf61oFlOWxhhkYIpYkVpMOVHUYU+1ZyiaRlYznsgIjGCDgBfXpVVdNR1w0e3C7T610SoNis2MN1PfPamhePmXarZHHqKhx7mbdzjH8OfZ7edYUDSS7UAxgqvr/Or95pwijZwi5WMqO/GP5106RgEZ4A4B71FPEA/OD6Ais2rGTV2cdb6NAsUbBQG4IPSki09YLrzivzMSGIHT0NdUbZWwWHH8qimtFXlcH0rKVzRGHcWAKkIBvzuB/Gnx2+ycyBB8wwx+laBgOcDP0oMJC4yec1F7lqyKoAIPBxT4UBOF6VK0DbcDOe9SWyMka7uT9KlldCaOMHGBg1fgjIAJAxmktl4zg5q8iBl9T7079ibFkmOS3KmdIyIjHtY4Gc5zWJqLpNebo38wKipuJ+8QOtdATcC2gFoFJ2/NwCQffPaqGqkSwzFvKJQoFK4Hz/xAeorS+hVJWPHwj7AG71MkW5QGxtAquozgbvrgVbBCLjJIFY3sdkSe1UqxXp71rR7UXIbn2rNhYFRtPPU5q2jcEhhih6BJXLEjqY8ZODUEhDEDO7HoKRmJIA70qqN2ScFaFJkqJGy4GcHBqF1YuPQ9xV11cjK88enFMWIrgk4J9+KLk8pCibDgkCp0XJ+XP1pcZfAUOf5VYWJMA5GeuOlUpE8o0JgDuPenjCDcecdqaGLsEbH4jgfSrQjBby0DFvUnjFVFofLYht5Q/3cgDgZ/nUrJtOS2OpI9KlihKRDlQDwvGdx7ikeILKyl2G3nnnJ75rWLbFyq4+EpkKVJQDBYcHJ6CnebtujsXayxttH3uDng+tVtwkdYslUX5mPbPYGiNTtMjDJXnd1Gf7tbqSQ+TuP4OQE8yLzFXfjbnA54/Gm6hdeU5ZD8hOM45IxgVBPcQeUcBtwOCQcEnHPFYs0nmSHJqJ1excKPMxl9MHfOSB2FQoC5BK8fzpNqggyHv0q3hdmwDGPSuWUrnU7RVkKmQMgDB7VKnbd1qEjC9DwKRXJ7c+lK+tjN6j5S0j4VvlqexhBfnkd81F8u5R1YelaNgmTuODik2Tc1tNCZLEAjGOlaSLsjG1wOeRjpVOxQIO+T3rajj3feAB74700tCuaw+B8bSeT03L0rUtJSeMnk+lUbJGLkFCV6da1UjVAMAk+mKtIyqNbD2Q7egHesG5Ki6YucDPStyRiGHYGs672lT7dfekZwdihM43cDjHGaoOiNKCeD7Vdlb5VHb1NZ0xPmk9cHtS2LXYa52Pz24zVaRWiZnX5Q3UAVJKdzg9CeR706RlmQHOPXFUrGi0Kpww+bknnFRTAcEEjtxTgpw2SODxTgN6j5sEc4pFNdR1nMDhXOMHIJ9a0WTcv3m/DgH3rDfeCG4BB49PpW1aXIliBIwwGPpW9Kq1octelb3kK/wApUsu5Tyc9c1JDbg7cthTk59B1696XcGAV/vEdNuc0Og2gAnjnk8CujmTOe7JNu1UPUHjg1IrDHLENnHTj8KgSRRtIzkHJwOKk3bRmP5gDzkcY9jUy7iswYFM55XHemb+xz757Um6VpfnBZGGMdPxpwiAfBXdkc+9Yy1KcULk45HXnIpG3bSeCKcIju4O0DpmoJQ2cfkazloSo3IXw27IwfemqeucHHGavCL5AeDTPs4/iG3Pesr9irIqhQzYU8j1qxFAeAcHvmpDaEMCPzFWoIfmxz+dTKRVhYYxgA9akk3LwR9KeUKNjnFQyyleRnr0IoTHGN2XG8sQorWyvI0RcMxPzMP4ePasPVk8u4HlxrGjIrBB/Dkd896uTyKkNvJ5dzK5y2Y3KhT6D3rKuZhLOzlJVLAHbISxz7mqb0sbU6dndHmcbqBhSR7HvViNjt+dj+FUogVOPlIHf0qzC3zEPjPtS0NYmhbOGyAPzq5ljjHy1TtUJOSAParQkG/aCMfWk2rA9wVy7lcEY7nvVmEF1wQMetRxIrNkAnPapVj/e58zGPypATpEFGOWo2d9uT2B61YjweNxz7VBMiE7OQSOMHFJjiuZkHmZdgcDB5Aq6gywyQg6lmGaijtAUBLqD34xU6BIgw2kk92PX3pq5o4x6CogZR0wp7inhCrltw247d6ikdmTYFLFj2701BswZSxOOVH8NUtxez0LbMwlCoeT687R9PWpiIBES5JJb7nQhQP5k4qlGyxspGSw5O5s065lZQzOUyew7CteexDp3ehXmdkbG8/MMHnn3qre3BaMxgFcnk1JLPvwQMY6D1rKuWZ3YAMM9M9al1LG0Kd9xVLjPmNuPbjtTHBIBAxntSQRvkeYuHA4z3pz5ZdvX1Valu5paz0IDGpO44B7VZt4woJPy+gz1qPyz5fy9j3/pU0ZLKARkkUWMqjEUMST69fanMoRfSnqMdySTyBUc5JIwAMdqdrIxvqJAmZAGH681rWUZDAjOD364rKtyTzn25FbVjlCuQMe3apQGvaKysGJyDx7GtqFM4OcH2rMtV4H94jjPetW3UggkEgdqtCky3boSSegzmtWEDKt2HUVRQkgbMjHJq7E3yqGHUVVjCbuMu9rYHcntWbcJ8205Oa03VQGLAqo/Ws6624ZscdqmQ4GXMcPtI4qpKAfy5q2+C4JwKrTLgnpg98VCXc0sUZBuGAMMelQKjICAck/zq1tyCM1HtI7YHTIqrlKVirMTtOcBj196rkyKBgEY75q5IuUYAcelVxuB69OM07G0ZEy7WiBbblv1ojV4pSVPyHnB7VAGIXGQFHanJKzsCOSOopXQcrNdCJNh3VYhRlX94dwrLR8OuTgE1pqSwGCcY7VcZ2OapSIDGQ7CNsBeTmpkO1chYyAOoJxj6UpRwRhTgDAxTG2YVlIyvTI/pWqqqxDpkm1uPlYA8k9if8KlVgJMs3I5BA60kauVG3BA6N0yKWOJmdZD82MjrRcnkJEG4kOec02WPbwvbqQM04M3mbR265NWI5ByGx8xxx2+tZyBRa1II4WIBJxj9ake3aRSCfrUykZxjJ7YpXCIuZGLGsLBcrpAY1CZb2zUxjC4wRn1FOLDYX4x2qvMwC72PWkkNK45nGQA2aq3DliBkfjTVlCn5uCeh9aie4S3dXYBmByFIyDSLUbPQvySA2sPlX62+1cMoyPx471iX7kzMWnFx8oHmevtV6XU2xxDanPUeWKyL6Zp33kIhxjag2j8qt2aKhF31PMkYnqw57A1PC3zcriqKbidowFP51dT5Y8KMjvSsXE0o5AuMvk9xipEkDSgAfjWfHJhMk7hU9uQo3E8jvRbuWkjWEoVcqGyPWhZx5gC8Z5NUlkyvzvwTgc1NAyfeXt2osUopGoj7Ytuefr2pXBByVDHoNp5qoD5noPQ9xSx8IyhyMHIzRbXQpIus5LiPglOQT2qeJZGjEkuOnB7/SqQdAiuzeYCMcdRU8Mo2hQCFbOAxHWnbUHfoRvOquVQ8+5xUwkdGIXbuH8fX8h3ptygCqPlC+3J+uaYoG0A4Cjpk5xTvYvmTQ8MzKN5YLknOOvvUd0qyKSCoHTA5JpxY7dhf5G4GB1pJCAzbv8AWH5c9jU3uFiuI9uzzCRzyO1V2LKXk252ng5zVhf3jMXXpwMN0PvSbWLbQM4HWki0rECIJQW5PHfjFTeWkUZ2n5j1zT5kARSCd/txmo7hvk2KOc5POcVUERO72K6tmToOBwB296RhyWyfambWYHbkKe+OatAkxHp8vSr6GE9CuAwI39Peo532NjIOfyqaU4jHqe+OlVH+fLY+UcZHrUyMb3NGzQhQvOT6citqzjAkGfXvWJYnAU88ccd66C3+d1MZyuOaS2uK5tWyZwc8DoRWlAFyNrd8kVR06P5fn6+taMSiLpn3z3qk7iNGGQLj/CpnfK7gDtIIJFU48KADwT61pRHdERnBH5Gq8jKWjKkrAwM4JCDpuFUJHLBgVG0jrWxKDKW+YbQOmMVkTuNzDBwOOaTRcHczHUbsjgZ71DL71ZmKE5/PNULhtrnH4VLNmrlabPmAqRjPNKsh2ngYPSmuwPJHOe9N3LxtzmmibB5vyncOT3xyap3AYjCHHqeuKsTkBuRx6+lQTKGzh8Ec47VRpB6lZH+cqMMR15prtJCWKruQ9u4qREETFufUYprSFWIbgEfrUnQnroTwt+8AbAyOgPQ1sW7btqrgkdRnmseMebhyy5AyO2K0LdcNnJ3kYz61LdiZxTNiNvm55b0NMfjcTgZ5Ix0rPWdopMtnHT15qf7QrMu/ofQUXMHBplm0LAOJTgDkDsasK6thieen0qmJDuy8iD07UpxIwZhhfZv51aehDjfUlO3cVxuP60/gEseFUce9QySMuF4HGcHj8KR1KqzSMMsMjPb2FMTJFnlQMSoJPGPSoGuHIZuSoOPr9KT5pGXezBRx8vp61FPuJ67QOnv71LVxqxK90rKBkk0NKAq7s5PY1UEoR+RuGeKjlmQNhVB79elTysq2uhaMiM3zleOgqNmQMrlVk2nO1uhqhHlpC2SMehyKc0zIMcE+44ocRNamsqmSIS/ZbFFI3DfIVOM4z16VkaiD9ueN1hjIA+WMkqOPWpluVkitjPbSFXR7YsCMOpP8PuD+FZ+qzE3bRqrwGJFiCyY3HA6n61VrIUU7nmsDgHfnPp9atnBjJ27ievOAKqwLhlGMoB09as4Hlnd8gPZaQJj4NqRFeGweVHQ1NBI27aRye/pVaLIxhQRnGPeplVkZmPQ/pRY3jYupgj58H+tOAWPBQYPaqYbaNoAYE1bUBE3hmbjnIp2uXsTQTyk4EJye9SiaVDlyFB4OR0FVY3KtwCVPbNWljZ0C5wBzU3LRbDFomETdeeOlEalZSXTAI571DFE6RNt+8ORg44q1bh5VzySo+XHNN23DoTkqdzfNv2/exwB2ApGTEahlZQepA64qSNGljbGQ+fmP+FSo/wC8ZQRkjG4jJ/CobM0yoIpGUMzZx0A7D1pfKYKDggk9cfyq8iplNqiNcYfmobmTdGAwKxqc/L1NFrI0Uncp+Wo3FOQDyPWpolQBXAKDkdOtSRRIG3EnYRwR61DKJWhVicYbHXpVKJTd9CKVzzgsBnKnFRSjCj5hhuc461P5TAb3bhOAM02VPNATkDrxVpWViZNIoRuF7/TFShjt+U8H1phiCSEKwwe3pT3+UKAfwNWkc1RoZIP3eCSOapzjDZ/l2q2/KnOcY6mqLAuQMDGazmupgpGnZOVjXgE9eT1rd06Repxlj0HGK5yBl35UPs6DNbelp5hVj61LNIq+p2VghZccY7mteKFTjso9az9OjHlLg5PpWlCWDfMRVpaGUt9ByohJ5ANXLcgrtbHqKpuyZA6AdxUiOCNxIA7Zp26kSV0WJvkGQB7msO5BDuS2dxzWhdOQQxJK4xg+tZvm7h8wAOcc0MqF1qUZmHRhyapTdP61eu+H9/as6ZxyD6ZqTZaohnxkc8d6p4beSp6Vbc/uix5qqdw7HnvSQJjlk3rgHj3qGNlOV7juRwaRnIXbjkHpVcSKjEAHJ960RUUyzK25Tkrke/FVsmb5mXIXjBPNRyAyd8Lnt1FMZMuNrNx7UmdUEjQtNjuCxKOMjArRcssIMeSy++M1lWjujnCgnuT2NbcbByNwHHB54zSSuRP3XcrKH2gsck84J5p8gUr8z7XUdAcVI8aS57Y6YpyRb3ysYJAxk0cuhLldXHsQbYbkzt7nrTUkEaIoU5Y9R0qeMMIXDLhc9AaaXGRGm0M3HXpSsQiTaNp/jb+9nPNRPkxEO7KF6ds0TKqR7UDYHJK0wORtGGL9eVzmqTJtoKBMWDmUbQMYxyahl8wEE5Hpn0qfBaQGTB74U1HIkrbyWVV7Fh2oRN7MqzT8A4wOxHNVpNoHHOew71LIm0sM7s9MVm3DPubaxBPAIGcU9zSNnoS+eELYDY9MdKhNxvcKis5PAABzmqTzyqzp5gY4x060kbTRFJAZY3HQr/Qimaci3NqMfbLS38/7XEYlKBo4DIrLnqPSqWs3HnXQKxyKI0WILKMMQBwx9zVkXEFna2jTXmoLI6eYUikAVVyRTdTtbfbNNDPcSsiRu3nMDuR+hB6jHoanlOe9mecwOBh35H92pnYEKV5BPWqaYJ3bgX/u1ZikH3Rw3TJ/wqDJMsxnB44bsSOKkIZyMklB6etVlUbQeWJ7f1qx0Ubjj6UzeOhZgjUsMY3d8VYyVBHG30IqspwR5fzH3qzlmjwx2t2FJ+RpuxoG9h1Unso4xVuFBFIjK7uOnPNQg9AUzjoKtQbNvCFD7UWsaXaJ1VCknOG6gVPbkqqhNu4joOKqRxmKPK4KEfMcVNCFUKQWIPpQ30B9i6rsA7ImAOOveh5FDBpAVcnB+lEflgsDv3yfcwOKR0IQbudh59B71LVhWQXJB3CM5bt3qDaZF4J80feBP61IwBf5BtHVSehNQOT5hwMFv4jVKzNI6ChzHKWQ529hTZZRw4JOQOAOhoaIysxcFSvA54NBt2YlRkydd2c1Vh3QsTBYwhLFx1Gec1IqeXuaQ8HkD1pzReWwyDnG7p1omVmjOcZHIB7VpFNmFRp6FK4QMdyjbkelVpn+UYGSPWrLHCYYms2ZmefaO/A5x+lD0OeRPGnmL3PuTmmyQlX2sMk9PSrUK+VFtI4/rQseQWYHHrWMncz21K9uuCfmb0rpdEUDkj6GufjBDgA8dq6PTDt2E4HuKlbm8fhOy0pAQTnA7VeYF84GMdzWXp7btvOQfetNpM9hk1vFHNJu4hXcMDg+1PMbIgYnIHUU+FQUChGDbuSxwKsT2CAOzTEuB8yqwO0/hW8aV1ch1VHRma9wxJBTI7ZNZ0zKzknrVu4GJCFbkenfiqcz8OcZrGSsbxatoVrgHP0qlNGSckZBq28mFyehqJ5gUGBk9KzZSbIgmI9uP0qs8Wcg9KvR4K4btTZAC3bpUq6DqZEkDRhupH8qpSKCzHIJHOSMGt24T5DlelZV5G2MhSV71pF30KTs7lLdl89UPXFO+faRn2G6mkkkADC9x6GnqolysYwCc8VbidEZE1mrMql1bjjK8D8a1YztO3Gc9c1HaKBGAevXFWICIt28jHXI60lG2pMp8wrS5YsDkYweMEe9MguGXIWIkk4NIxO87Bv3cZPaqwO1yGdlQcj60PRDjFNGmrkgDPXjnvSuqoGAUbiCuR2NVI7lhCueQOefWpo7lVj+eIhj0BqbEOLWqHW6MW5yWxyCcipmbKsAW9AR2PpUTYLFVYkbc+9KD5SBVG0gY5P3qlIh73Ig3ly85J7miYzOGKlWT1PaoFXDuRKWyOnQU5nPA3eXgY5700NxKt0ZPLG0hB0AqvNCxQZyjY6MeSamkYeYpcgN/d7Gop3BQ/NhgfrijzHZooPDHuG47ZM80yWKVc7G4PbNXSh8ouwHTriqbxuDuaQEdsHtVBfqXIJRaW1uNRnj2kF4ozbCVkXOM5PTJ7VV1Ge4jeSG4lWWCYrN5qjHmDHy/QD07VNFeQm2RLu1S5EQKqzMVYL1wT3FU9Z3/aA7GNS0SMkafdRMcAD2oexjfXU4GEliQOKkV23EvyByBUKcMOOB1qdfuk9BWSbZCZcjIIUDkegqy2NgyST0FVbV9uSDz61ISDIGLe/PSjoWmWY+MEsSO2KnHzr8zDGeOcEVVUgg7XGPSposHaAd316Cjobxdy+nDY37hjHvVuEqCu8qB71QQD5v4T2NSRZ5cnlfWhq6LNzMflMoUgtzg9MVREjRsjoAFzgg/wA6iSYSHaQx4qXIKH5Rj6dBRyjirbmj5+4KeFKjAIpGmEsXyDr94etQwjMO1lBOeCOtSbmVmjYYx3xVWErJ6EoSNRkKSrDkdcUnEiEbcLnI4pEuPnZCm0HrS+YqKVL8nkYpqKE2yORGZMICD7mmRRhRgswk6VZWSIqd4YlhjFJNFEYsgbeOKpxFzNaEfCoNzNuHeo3JZ2ZOGIxn1pY4vlOWyQPzqKeRt/y/ex24q47WIfYo3jGMnt35rNtJS9wW27gOOnerOtzf6Odw+YjFVdJCmEMeGY1nVlZ2RCWl2a7HG3POak5SJSR1zjI6/Sq0jjPf296invGWLYSzKOApPAHtWK1eplJ3GxyjzsYAOeTXT2LK0fBwQOK4dHIuOprpdJu8he5HBBqqe5sldaHaWUrLgfez/FWxBNIAsgQvGvf271zcFyuzO4gkflWrbXkih445SqMAGOf0rtgrbnPPvY6iyktJWaQrjd8o3c4xT9QdhbSGGMRRR4Qvjhj1wPWsAXpjiAUrgA8kdfrVG5vJH6yO6jkbmzXQpJI5lScpXRJdzKW3btprPubpVXAG1T61DcTjDEkg471z95dv0DZ74rmkk3c7IxubLXAx1+nNME5YEY5Brn2u/wC8as205YBtxz1rFotuxuiXCjPX0pWlDMKyPtXvzVuCQEBs8moaJckaBIbnPas29jyC2TntmrQky3XjtUFw4aMhiDmp13KTuYyg+YG4z0I7Vp2QVCQynkcelZkY3TsCSMdqv5bb8vTHNdUVcpdiyr7gGLMMHHy9qJ5iikINpHaq4kA+ZuB1IXpRGrPGTuxnna3pUtGsUi9FI+3CAEMu76GqYDNLmRjs5Kg881KDvBQcN/e9aZMZ925wqhSMYFRa+5pHfQlRMEZcE9Dj+Knu0wmVU2lO5x6f1qtG7qquCm5s98ipzGyxqyBwG4PYCk12Kej1LFnO2WZlPJ69zU9w8bk/OWwMHHas+4DJjyz+IFSYLRKQy4xycYJPoamPmYTir3I7fETsq/X5qZMX3gKwC8Z3Hg/4UydmaUbDg9xmkkcOdoUhSKodraj3dVJIQg45yMioBGoO9jkkfnViBwUaLGfrVe5VI2G7HThgalIzb1sNk2+SRj5T71Ui2LMnmKzwjJZA2049jTDJIJCQpwP4R0PvUtvE11cpFG6hnOA3YfWqIloiSW40raQ9nd56bftAHH5Vm6pcrc3gZIGijWNYlDNuO1R61oH+ytrJ593Jt/5aLGoH1AJzWff2/wBmuNqOZkaMOjqMblPQ4pO5jzI4VGGMkE59809XLYzkegqCDLLwcGpR8v3l61jcIliPAHJyw7CpyxJ3FNzDofeq0YUKCDgHt1qRZm5wOPSqXc0iWYZgNoySw/hxVmMqQD0weg7Vn24KysWOT2Bq7GxDNwACM4osbx0LYL5XBH/1qsxBnPzN9DVOHJGGO3npjrVxFwo6j8aZdyxHESxO/wCUHpjrVkM3I/g7YNV4FZACBu61KVyFwPmFPYL3ZLFKPMLRyfOowcdjVhWmIaR23n3FUcIrZCbT3xVm3beyjJH16GmtRssqwSQNIre+7vUMhUBl2Dcfu80pMkhw4BGfuk0SpGp3b+V55q2xWCNQQqu+09eDT5WYjBKkg5HNNQGZSAcY6Y7VItuykAjK+woRL03EjUMdxXp0weKbJsHzEjPvVtYwi/KDxz1qjcKHB4yO4qr2MtznPEUpbjbx27Zpmm48jC/wjPJ/lVjWIN8e4DlTWRBMY3BHDr0JFc03+81NJL3NDdkc+WCuDxisPUtRjtkLSjjHbqKvfaiy9iT3AxiuT8WFz8vtVyhZcxyx+KzNrS7+21BW8h/3iHlDwfr9K6XTX54614lp96+m6pDOGO1W+YE9R6V7Do8yzxR3EZyjgMuPSiK2sXCTTdzsbeXCAZwBzkVbSVlJOcYPXOTWHBKVbDZ55wOoqczAMFwU5/E11x7lclzbW5IB2tkMMYIqOaQNuZmyePas3zSRgnJpXnO0rg+nSqDlsPu5CFK5OQKx5ACeTk1cmkJGCMGsnU7xbZVKgNKR8q/1NZPXYT0Q26kitoDNPIscS9WY4Fc9d+NdNtxi282bB6gbQR+NYWtpdandub+Usin5EHCj8KoSaHHsJXJGM5oUHa6RjJ66na6T4stL6VYwWjf0ccfnXUw3SkbgfrivKLHTypVSCcHIKjmut06SaNQHzx29Kixpy3Ozju8jhvzps1zkYIGelYaTnPzE4qxDK0kiqqj5TnPeocbspRaLyKFkOR3z19KtQv5iYBAOc59KrxRMwJzn6/zq3HtDAqc8Yx0FdCGmIWYsPlx3x2qS33GQs7c56k5H0xQYpDz26nNEcbRHcWJz24FJmykmrEyMoOU7dT1JpjRs0u12Zscgeo9KehSKQGNDk9D1qWSEShVEhGD0qLFJ8rKcgeJVLxsSx4QcAVbW4xl5DtIHC9cH3FLID5TlVJK8A55rKw+X24U7sk5qZLsUnzos3E8r87hknJUcYpwnEgIj2k9Dk4ANZ4jdk+aX2z7VMsOVUKWXb/EKzSaRbsi04RioLfMfu47U2VtmwKyj19qrgtkgPx3JFJKWklTO0gfhVWuZPckEoVDIxxzngUy8kLqvl8jrzSyOqgqrcZwRioLplUq4PHtTSMm9SPEilinVvbtSoXW4je33+eCCmwc5/rUKTlkOVPXgjnAqMSMJB5eS+flK9SewFDMZ3e5ql7s/NJocTsTkt9nYfmM4rLv3uzeO12rCUgfIV27V7ADsMVf1C31a4nWRlEbOAGT7QFJbHXGeprEufPSdxOsglQ4cP94UmznZxEWBjnPtVgLlhnkiqiEhu2aso3I9awNESglVGDznpSwMGLcYIPBNIMgY7Hn3pQ+eM7eO3U1ZotWWolH3t2M9QRV22KMw+X5lP3jVCIFsZyQO9WYG5HYDqBTWxstTRXnJB9vpU8fyrheOOeOtURJ5mCwO3vtqQy4IA3D2NMtJl2KVV+XLK1XFzgEnj16VRhVpCT1I75q2E4xIWJ9BR6lNpaExIWX5yQx6EU1t/nHzAMdmA5pvmFVBYkjsCO9I5bdyeSPXqaEiok8Tjzfv59x1FTypAFy6ktjgmqiECZAE5PXPT86tALkruMgPUEdKvoDeoW8y5ARcMvcmrxkIUFSoJ/GqaxADdjGT2qQt5aHjHtTTM5pMJZi3yLxnk45xUD4QYdfxz1pYyN3TPGc0+TJUkc9hmk3cFFLYpuqurArk96wtR07Y29FJQ9hXThQpHqaeY1ZSCufw4zSlBTJlLl2OA80RHB+mM9Kzde2SQoSvOMAg9a6rWdMWaQmMBJCcgjgVyWp20sZCyD6EdDQ9I2ZnyXd0cdeWxL5GeOa7f4baoojbTpjtdWLp9DWN9lEhwRx61JbWzW1xHPAcOhyKxjPlHOB6yz+Wo24+vpUayrkMwYn1zWJp2pi9tlxIQw++h4IP+FWHkcBgSV967ISuiYuy1N6KUAkgj6HqRQ8rHaRkjPY1hx3ucDqffkGrsVypHbn0q+YG3EsXt0lrbO784HfufauP8ya6neZ2GSe/8IrT1t5bmVERsRDgj1pkNsifu9ueKlNEx0Wpm3FkJi7Idx7FeefaoorGbeoaM9MZFdHDCFCKoXAP3VGMir6xIpBPUH6Vdm9hX12M3T9HVFDuAPc1LcqoPGABwCev41dvLpI48ZGcdqw5rlpXIVcg0m1HQqKctWPZ2YkA5J6KP51t2Fs0cYJYAkZOB1rM0q2JdSQWY966mzjyBjAJOBkVHmaO4sMY2YX0wSRTgoXoRnvVwwhMAc596bLGAdygHnHSlzCSGJJtTBGRTmXkEhSP5fjT4gG4YA57UjpnIONq9FHf609xLRjShHzKcc5pn7tBmVmdhz8vQUpbCk7gD1zjt6VDujVw3zN32t0qWarzASPKCAGVAM5qo8SO3BbYOlXslnQ8LxyP7tNZmeTICk9h3qdS1KxDDGnG889NpFPkKHhRwTjrTyioxMhyTzk1E2zpuGM01sRzX1ILgDIYKRt6t61EZEC89B0qzPICNpJK9qqqcglhlh0zQ0w5rrUF5O4A5Pb+tV5Gydo5x+FS+YTljjdjoTULbQuQeG9eooZm3Yiy0ZLE4X270+yufsd7DchAQjbiCcEj29DVaZygA3Kw9+1TWEiRahbTXG0xK4ZiRkD0OP1pMwqXHT22m7maW7uo93IWS1+YfjnBqrqs4uLxDGHjVIkjUS8OygYDH61dm1DNxLY6tcLdW7Enz1beYmPRkPp6iode2fbI9k0cyLbxAMpyDhcUnoYt2POyduWH41PGwJxnGOpprAYxx+HSmIQG2qD0ya5Vc0Lg246g98GnPg7TlQPSoouB8xqZcbf7zHjkdK0LRLC4GN3IHQ1Y8wkfoKqqVGQSePTtViIgZ5AGORVHRBqxZhYqBwA3cZqYneFwOCepqsC208YXufWrVtGCAchcc09zTm6mhbKU5GanLOcljgdc1VDgHG8FvbvU8ZJGFOWx36UELuSRtuz8xwOuafF5ZbJB+lQK5KsQBnoSRSSSNEqgEYA4x3p6FLV2LbOBxGCQOuetSKECb16d81lR3fJ8w/MfT+tXoizouRjnmqt1NGuVGhE+5OAc+9KFPWRvm+nSordSrhVyV96tEDJGefShsxctSuQQjBcbSc0+OPAwSBTn5ZQAMClTrtPXqPpUofMDRkrgAYHepApVDnP3etOBH3R9aecMwx1PAJqkZSZkT25c5YZBrKvtPWRWGzr3rrWhQqSwB4way7qMgvgfdHGKpdmEZ82h59e6YYHyg+Q9DVUIUQ5HNd5PbqYgCM5XI+lY1zYIzhQpBPPFYSpdi+a+5zEbvbyiWJird8dxWva6vBOu2ctG4HII4P0q6dJjYkE4wKZ/YkT7vlPy8fWiKmtCZcrIpLmISZWRSvHOelSRalEoIJ79qY+jJGgKgt3I9KVLJYmJVdvGeRWrjJkJ3LQneXAiXJ9W4q5bQtyWwWzzRZIoAOMsODV4oMbgNu3t6fWtoxsiZPoQDcjEjGenrTZrgqcDr3PepGUAfKOvOTUaxbuTgjNNu+hUYrqVXjedgMkj+dWrexVQpO7HfNXLW2OMgAEcZ681oR221U39AOlCsir6jba2GwFeOeMdhWtbJyBgg9aZaxYjAYdeQKtRBlK7iMnis2O5ZMK7Qx5qKa3yBnIB7VI0ny8dSaUknac57kVIo3RVCKJMAdOtDAfMRjdjqasSAHJXt3qHO3J6gDnFCZRX3AYB+Y5/h6fWiWJSdwGcfxE0j4dvkJ+lQSOyk/xH+VBer2IrhgCCqkk96e0mz5fkX1I609SHXLoDjoB0FV5JP3bKqrknqOtL1KHyTK4VQDsHcVCD+8Ow5XoQ1RKxUkfMfanxuTydu1jySMUyXpsNMgx+7bcRVWTaflBct1JJp0qsr8A9eCKryFg3UE98VV9AsK2CoIbBPXJqKQkbskcDpUgCSAblO3qc1C4ySqcVBDaIW2s2Cev6Uq+ZJIkUSFnY7QuOpqJlCyZLE564qfTpBHfRSPuEXIznJXIIyPpnNG5zzZJ9htw5SS6fzMElkhLRjHfPUgeoGKoXMUkEzwyhVkTptOQQehHsRXReRJ9ttroLdNLEqqEjXMbgDHEmcBD1OenNYeqOkt0saMrCKJYvMB4Yjrj2ycD6UmjnvdnHYHz8VAGO/HYUUVzm/YsqSIw3erG35uSTxmiiqRRLtHI7HrUsbEFwMYwKKKtdDWPQmt/mJB6elWo2Krx3OKKKo26E1v8AMGY9QeKs+YwQkHnpRRUoOo5BwRzgc4pwO8LmiitI7Ma3CGFEYlV5rQBOwDs3Wiin9kVTcuWoBDHuKewzGM9zzRRU9jLqNIAY09vlGB/F6/Wiih7jYv8AHUsLEiPPpmiihGciWdyC4z0IqlIM5HY4NFFUZxKV2oUxoPunI/WqqgMTnjPBxRRQbLYjRRhh6GrEUSs7AjgHAFFFVHoTLYfqUKRiPaMZrHlUE89xRRVsmmWrFQfzq0v+sx2xRRREHuMIBPTuaeigKv0z+tFFHU0NSGJBgAcZq2ijavHeiipkY9S1Goyp7jmragbV+uKKKl7GgrgYJ96kUAoPpRRUofQqSAAkADpULKGlYHofSiik9zWIwj59vYZqDaGDE8kUUU0LqVGYqFxxUMvI9Dg8iiipZsuozqOT75pNgMGe7HBooqupLKjOwbYGOKIjtGeuTg5ooqmRMY/+rJ74qFRlyvONufxoopPYyZA7HIPfpTHHyg980UVK2MZ7CuzbV+ZsP1APB/CmRD5jnkdMGiioZg9j/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous erythema is present on the periorbital skin in this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29793=[""].join("\n");
var outline_f29_6_29793=null;
var title_f29_6_29794="Petechiae in Henoch Schonlein purpura IgA vasculitis";
var content_f29_6_29794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Petechiae in Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clusters of palpable, pruritic petechiae on the thigh of a patient with Henoch-Sch&ouml;nlein purpura (IgA vasculitis). These lesions could be mistaken for thrombocytopenic petechiae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29794=[""].join("\n");
var outline_f29_6_29794=null;
var title_f29_6_29795="Division isthmus";
var content_f29_6_29795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Division isthmus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dandy clamps in place, with isthmus divided at its lateral aspect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29795=[""].join("\n");
var outline_f29_6_29795=null;
var title_f29_6_29796="Malleable penile prosthesis";
var content_f29_6_29796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Malleable penile prosthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 501px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of American Medical Systems, Inc. Minnetonka, Minnesota (www.AmericanMedicalSystems.com).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29796=[""].join("\n");
var outline_f29_6_29796=null;
var title_f29_6_29797="Methyldopa: Patient drug information";
var content_f29_6_29797=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methyldopa: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"     see \"Methyldopa: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/10/20645?source=see_link\">",
"     see \"Methyldopa: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methyldopa&reg;;",
"     </li>",
"     <li>",
"      Nu-Medopa",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methyldopa or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease or if this drug caused liver problems before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696882",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron products within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699444",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11795 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29797=[""].join("\n");
var outline_f29_6_29797=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195033\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029930\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029932\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029931\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029936\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029937\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029939\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029934\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029935\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029940\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029941\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=related_link\">",
"      Methyldopa: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/10/20645?source=related_link\">",
"      Methyldopa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_6_29798="Methamphetamine: Pediatric drug information";
var content_f29_6_29798=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methamphetamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?41/25/42390?source=see_link\">",
"    see \"Methamphetamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/1/12309?source=see_link\">",
"    see \"Methamphetamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Desoxyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Desoxyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1024415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Amphetamine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anorexiant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Central Nervous System Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1024441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/25/42390?source=see_link\">",
"      see \"Methamphetamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder: Note:",
"     </b>",
"     Use lowest effective individualized dose; administer first dose in early morning: Children &ge;6 years and Adolescents: Oral: Initial: 5 mg once or twice daily; may increase by 5 mg increments weekly until optimum response is achieved; usual effective dose: 20-25 mg/day; dose may be divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Exogenous obesity:",
"     </b>",
"     Children and Adolescents &ge;12 years: Oral: 5 mg administered 30 minutes before each meal; treatment duration should not exceed a few weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"     Oral: Initial: 5 mg once or twice daily, may increase by 5 mg increments weekly until optimum response is achieved, usually 20-25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Exogenous obesity:",
"     </b>",
"     Oral: Initial: 5 mg administered 30 minutes before each meal; treatment duration should not exceed a few weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desoxyn&reg;: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F194098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088582.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088582.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13733326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid late evening doses due to resultant insomnia.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3462067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store below 30&deg;C (86&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1024416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages &ge;6 years and adults);  short-term (eg, few weeks) adjunct therapy to treat exogenous obesity refractory to alternative therapy (eg, repeat diets, group programs, and other drugs) (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Desoxyn&reg; may be confused with digoxin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F194102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, dysphoria, euphoria, exacerbation of motor and phonic tics and Tourette's syndrome, headache, insomnia, overstimulation, psychosis, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Change in libido",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, unpleasant taste, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Suppression of growth in children, tolerance and withdrawal with prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1024420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to methamphetamine, amphetamines, other sympathomimetic amines, or any component; advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states; history of drug abuse; concurrent use or use within 14 days of  MAO inhibitors (hypertensive crisis may occur)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13733257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with mild hypertension and in those receiving other sympathomimetic agents; use is contraindicated in patients with moderate to severe hypertension. Use with caution in patients with diabetes mellitus; antidiabetic agent requirements may be altered with anorexigens and concomitant dietary restrictions. Prescribe or dispense least amount feasible to minimize chance of overdose.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1024421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious cardiovascular events, including sudden death, may occur in patients with pre-existing structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of amphetamines in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of amphetamines. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould, 2009).  In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2-24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31-1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57-1.89) users compared to nonusers (Cooper, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as methamphetamine, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Stimulant medications may increase blood pressure (average increase: 2-4 mm Hg) and heart rate (average increase: 3-6 bpm); some patients may experience greater increases; use stimulant medications with caution in patients with hypertension and other cardiovascular conditions that may be exacerbated by increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Psychiatric adverse events may occur. Stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychosis. New-onset psychosis or mania may occur with stimulant use in patients without a prior history of psychotic illness or mania, even at standard doses. Stimulants may induce mixed/manic episode in patients with bipolar disorder; patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. May be associated with aggressive behavior or hostility; monitor for development or worsening of these behaviors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use of stimulants in children has been associated with growth suppression; monitor growth; treatment interruption may be needed. Appetite suppression may occur; monitor weight during therapy, particularly in children. Stimulants may lower seizure threshold leading to new onset or breakthrough seizure activity; use with caution in patients with a history of seizure disorder. Visual disturbances (eg, difficulty in accommodation and blurred vision) have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Amphetamines possess a high potential for abuse",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; misuse may cause sudden death and serious cardiovascular adverse events",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; limit use to weight reduction programs where alternative therapy has been ineffective",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; prolonged administration may lead to drug dependence; abrupt discontinuation following high doses or for prolonged periods may result in symptoms of withdrawal; avoid abrupt discontinuation in patients who have received amphetamines for prolonged periods; once tolerance to anorectic effects occurs (within few weeks) therapy should be discontinued. Amphetamines may impair the ability to engage in potentially hazardous activities. May exacerbate motor and phonic tics and Tourette's syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F194092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1024434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Acidic foods, juices, or vitamin C may decrease oral absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2890217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse effects have been observed in animal reproduction studies. Methamphetamine and amphetamine were detected in newborn tissues following intermittent maternal use of Desoxyn&reg; during pregnancy (Garriott, 1973). The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1024445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CNS activity; blood pressure and  heart rate (baseline, following dose increases, and periodically during treatment); sleep, appetite, abnormal movements, height, body weight (BMI), growth rate in children. Patients should be re-evaluated at appropriate intervals to assess continued need for the medication. Observe for signs/symptoms of aggression, hostility, or depression. Monitor for visual disturbances.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1024435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amphetamines are noncatecholamine, sympathomimetic amines that promote the release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals, thus increasing the amounts of circulating dopamine and norepinephrine in the cerebral cortex and reticular activating system. A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition. Amphetamines also weakly inhibit the action of monoamine oxidase. They peripherally increase blood pressure and act as a respiratory stimulant and weak bronchodilator.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1024436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via aromatic hydroxylation, N-dealkylation and deamination to several metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine primarily (dependent on urine pH; alkaline urine increases the half-life); 62% of  dose eliminated in urine within first 24 hours with ~33%  as unchanged drug and remainder as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1024446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/1/12309?source=see_link\">",
"      see \"Methamphetamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide with each prescription and refill of methamphetamine. Serious cardiac effects or psychiatric adverse effects may occur; notify physician of any heart problems, high blood pressure, or psychiatric conditions before starting therapy. May reduce the growth rate in children and has been associated with worsening of aggressive behavior; notify physician if child displays aggression or hostility; ensure that physician monitors child&rsquo;s weight and height. Avoid caffeine. Patients with diabetes need to monitor serum glucose closely; may alter antidiabetic medication requirements. May be habit-forming; avoid abrupt discontinuation after prolonged use. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May cause dry mouth. Notify physician if blurred vision occurs. Seek immediate medical attention if chest pain, vomiting, or difficulty in breathing or swallowing occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1024448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment with methamphetamine for ADHD should include &ldquo;drug holidays&rdquo; or periodic discontinuation in order to assess the patient's requirements, decrease tolerance, and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, \"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 128(5):1007-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at file://americanheart.mediaroom.com/index.php?s=43&amp;item=422",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists (ACOG) Committee on Health Care for Underserved Women, \"Committee Opinion No. 479: Methamphetamine Abuse in Women of Reproductive Age,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):751-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29798/abstract-text/21343793/pubmed\" id=\"21343793\" target=\"_blank\">",
"        21343793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, \"ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29798/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garriott JC and Spruill FG, \"Detection of Methamphetamine in a Newborn Infant,\"",
"      <i>",
"       J Forensic Sci",
"      </i>",
"      , 1973, 18(4):434-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29798/abstract-text/4784309/pubmed\" id=\"4784309\" target=\"_blank\">",
"        4784309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golub M, Costa L, Crofton K, et al, \"NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,\"",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2005, 74(6):471-584.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29798/abstract-text/16167346/pubmed\" id=\"16167346\" target=\"_blank\">",
"        16167346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MS, Walsh BT, Munfakh JL, et al, \"Sudden Death and Use of Stimulant Medications in Youths,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2009, 166(9):992-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29798/abstract-text/19528194/pubmed\" id=\"19528194\" target=\"_blank\">",
"        19528194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaGasse LL, Derauf C, Smith LM, et al, \"Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(4):681-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29798/abstract-text/22430455/pubmed\" id=\"22430455\" target=\"_blank\">",
"        22430455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S and AACAP Work Group on Quality Issues, \"Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, ;46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29798/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder [Corrected]: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29798/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17133 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29798=[""].join("\n");
var outline_f29_6_29798=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709038\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194083\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194084\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024415\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024441\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194067\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194052\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194098\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874887\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733326\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3462067\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024416\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194104\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194102\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024420\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733257\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024421\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194092\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194061\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024434\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194062\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2890217\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024445\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024435\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024436\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024446\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1024448\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17133\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17133|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/25/42390?source=related_link\">",
"      Methamphetamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/1/12309?source=related_link\">",
"      Methamphetamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_6_29799="Juvenile xanthogranuloma periocular";
var content_f29_6_29799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75895%7EDERM%2F56332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75895%7EDERM%2F56332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple periocular lesions in a young child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraocular juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29799=[""].join("\n");
var outline_f29_6_29799=null;
var title_f29_6_29800="Glyburide: Drug information";
var content_f29_6_29800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glyburide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/38/15973?source=see_link\">",
"    see \"Glyburide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/22/37222?source=see_link\">",
"    see \"Glyburide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DiaBeta&reg;;",
"     </li>",
"     <li>",
"      Glynase&reg; PresTab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Glyburide&reg;;",
"     </li>",
"     <li>",
"      DiaBeta&reg;;",
"     </li>",
"     <li>",
"      Dom-Glyburide;",
"     </li>",
"     <li>",
"      Euglucon&reg;;",
"     </li>",
"     <li>",
"      Med-Glybe;",
"     </li>",
"     <li>",
"      Mylan-Glybe;",
"     </li>",
"     <li>",
"      Novo-Glyburide;",
"     </li>",
"     <li>",
"      Nu-Glyburide;",
"     </li>",
"     <li>",
"      PMS-Glyburide;",
"     </li>",
"     <li>",
"      PRO-Glyburide;",
"     </li>",
"     <li>",
"      ratio-Glyburide;",
"     </li>",
"     <li>",
"      Riva-Glyburide;",
"     </li>",
"     <li>",
"      Sandoz-Glyburide;",
"     </li>",
"     <li>",
"      Teva-Glyburide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Micronized glyburide tablets are",
"     <b>",
"      not",
"     </b>",
"     bioequivalent to conventional glyburide tablets; retitration should occur if patients are being transferred to a different glyburide formulation (eg, micronized-to-conventional or vice versa) or from other hypoglycemic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Regular tablets cannot be used interchangeably with micronized tablet formulations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Regular tablets (Dia&beta;eta&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 2.5-5 mg/day, administered with breakfast or the first main meal of the day. In patients who are more sensitive to hypoglycemic drugs, start at 1.25 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adjustment: Increase in increments of no more than 2.5 mg/day at weekly intervals based on the patient's blood glucose response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: 1.25-20 mg/day given as single or divided doses. Some patients (especially those receiving &gt;10 mg/day) may have a more satisfactory response with twice-daily dosing. Maximum: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Micronized tablets (Glynase&reg; PresTab&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 1.5-3 mg/day, administered with breakfast or the first main meal of the day in patients who are more sensitive to hypoglycemic drugs, start at 0.75 mg/day. Increase in increments of no more than 1.5 mg/day in weekly intervals based on the patient's blood glucose response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: 0.75-12 mg/day given as a single dose or in divided doses. Some patients (especially those receiving &gt;6 mg/day) may have a more satisfactory response with twice-daily dosing. Maximum: 12 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Management of noninsulin-dependent diabetes mellitus in patients previously maintained on insulin:",
"     </b>",
"     Oral: Initial dosage dependent upon previous insulin dosage, see table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Dose Conversion: Insulin to Glyburide",
"     </caption>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Previous Daily Insulin Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (units/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Initial Glyburide Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Conventional Formulation",
"         </i>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Initial Glyburide Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Micronized Formulation",
"         </i>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Insulin Dosage Change",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (after glyburide started)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.5-3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Discontinue",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (increase in increments of 1.25-2.5 mg every 2-10 days)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (increase in increments of 0.75-1.5 mg every 2-10 days)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Reduce insulin dosage by 50% (gradually taper off insulin as glyburide dosage increased)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Regular tablets (Dia&beta;eta&reg;): Oral: Initial: 1.25-2.5 mg/day, increase by 1.25-2.5 mg/day every 1-3 weeks. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F176705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F176706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use conservative initial and maintenance doses and avoid use in severe disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1.25 mg, 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DiaBeta&reg;: 1.25 mg, 2.5 mg, 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [micronized]: 1.5 mg, 3 mg, 5 mg, 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glynase&reg; PresTab&reg;: 1.5 mg, 3 mg, 6 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals at the same time each day (twice-daily dosing may be beneficial if conventional glyburide doses are &gt;10 mg or micronized glyburide doses are &gt;6 mg). Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to diet and exercise for the management of type 2 diabetes mellitus (noninsulin dependent, NIDDM)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F176745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alternative to insulin in women for the treatment of gestational diabetes mellitus (GDM) (11-33 weeks gestation)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F176756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GlyBURIDE may be confused with glipiZIDE, Glucotrol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dia&beta;eta&reg; may be confused with Zebeta&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Micronase may be confused with microK&reg;, miconazole, Micronor&reg;, Microzide&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, erythema, maculopapular eruptions, morbilliform eruptions, photosensitivity reaction, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Disulfiram-like reaction, hypoglycemia, hyponatremia (SIADH reported with other sulfonylureas)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, epigastric fullness, heartburn, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Nocturia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, pancytopenia, porphyria cutanea tarda, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatitis, liver failure, transaminase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuretic effect (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glyburide or any component of the formulation; type 1 diabetes mellitus (insulin dependent, IDDM), diabetic ketoacidosis; concomitant use with bosentan",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse reactions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal, hepatic, adrenal and/or pituitary function; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in older adults due to increased risk of prolonged hypoglycemia (Beers Criteria). Rapid and prolonged hypoglycemia (&gt;12 hours) despite hypertonic glucose injections have been reported; age and hepatic and renal impairment are independent risk factors for hypoglycemia; dosage titration should be made at weekly intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Glyburide tablet formulations:",
"     <i>",
"      Micronized",
"     </i>",
"     glyburide tablets are",
"     <b>",
"      not",
"     </b>",
"     bioequivalent to",
"     <i>",
"      conventional",
"     </i>",
"     glyburide tablets; retitration should occur if patients are being transferred to a different glyburide formulation (eg, micronized-to-conventional or vice versa) or from other hypoglycemic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F176743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: GlyBURIDE may enhance the hepatotoxic effect of Bosentan. Bosentan may increase the metabolism of GlyBURIDE. GlyBURIDE may increase the metabolism of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of GlyBURIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of GlyBURIDE. Management: Administer glyburide at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F176694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Caution with ethanol (may cause hypoglycemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Herbs with hypoglycemic properties may enhance the hypoglycemic effect of glyburide. This includes alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer dependent) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies differ by manufacturer labeling. Because adverse events were not observed in animal reproduction studies, one manufacturer classifies glyburide as pregnancy category B. Because adverse events were noted in animal studies during the period of lactation, another manufacturer classifies glyburide as pregnancy category C.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Glyburide was not found to significantly cross the placenta",
"     <i>",
"      in vitro",
"     </i>",
"     and was not found in the cord serum infants of mothers taking glyburide for gestational diabetes mellitus (GDM). Nonteratogenic effects such as hypoglycemia in the neonate have been associated with maternal glyburide use. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. The manufacturer recommends that if glyburide is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date. Although studies have shown positive outcomes using glyburide for the treatment of GDM, use may not be appropriate for all women. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of type 2 diabetes mellitus during pregnancy. Insulin is considered the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not enter breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1699343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data from initial studies note that glyburide was not detected in breast milk. Breast-feeding is not recommended by the manufacturer. Potentially, hypoglycemia may occur in a nursing infant exposed to a sulfonylurea via breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F176685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with meals at the same time each day (twice-daily dosing may be beneficial if conventional glyburide doses are &gt;10 mg or micronized glyburide doses are &gt;6 mg). Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F176683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diabeta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (50): $24.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $95.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $175.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (GlyBURIDE Micronized Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (100): $37.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $60.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (100): $107.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (GlyBURIDE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (100): $27.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $45.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $77.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Glynase Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (100): $97.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $164.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (100): $259.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypoglycemia, fasting blood glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F176674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F176686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Glibenclamide (NZ);",
"     </li>",
"     <li>",
"      Bendix (PH);",
"     </li>",
"     <li>",
"      Benil (SG);",
"     </li>",
"     <li>",
"      Betanase (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Betanese 5 (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Bevoren (LU);",
"     </li>",
"     <li>",
"      Calabren (CZ);",
"     </li>",
"     <li>",
"      Clamide (HK);",
"     </li>",
"     <li>",
"      Daonil (AE, AR, AU, BD, BE, BF, BH, BJ, BO, BR, CH, CI, CL, CN, CR, CY, DK, DO, EG, ET, FR, GH, GM, GN, GR, GT, HK, HN, HR, IE, IN, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NO, NZ, OM, PA, PH, PT, PY, QA, RU, SA, SC, SD, SG, SL, SN, SV, SY, TH, TN, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Diaben (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Diabenol (TH);",
"     </li>",
"     <li>",
"      Dibelet (MY);",
"     </li>",
"     <li>",
"      Euclamin (PL);",
"     </li>",
"     <li>",
"      Euglotab (PH);",
"     </li>",
"     <li>",
"      Euglucan (FR);",
"     </li>",
"     <li>",
"      Euglucon (AE, AR, AT, AU, BD, BE, BF, BH, BJ, BO, BR, CH, CI, CO, CY, CZ, DE, EC, EG, ES, ET, FI, GH, GM, GN, GR, HK, HR, IN, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NZ, OM, PH, PK, PT, QA, RU, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Euglusid (CN);",
"     </li>",
"     <li>",
"      Gilemal (AT, HU);",
"     </li>",
"     <li>",
"      Glamide (TH);",
"     </li>",
"     <li>",
"      Gliban (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Glibedal (HR);",
"     </li>",
"     <li>",
"      Gliben (IT);",
"     </li>",
"     <li>",
"      Gliben-CP (HK);",
"     </li>",
"     <li>",
"      Glibenclamid (HR);",
"     </li>",
"     <li>",
"      Glibenclamid Pharmavit (HU);",
"     </li>",
"     <li>",
"      Glibenclamid-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Glibenhexal (LU);",
"     </li>",
"     <li>",
"      Glibesyn (MY, SG, TH);",
"     </li>",
"     <li>",
"      Glibet (IN);",
"     </li>",
"     <li>",
"      Glibetic (IL);",
"     </li>",
"     <li>",
"      Glibil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Gliboral (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Glidiabet (PE);",
"     </li>",
"     <li>",
"      Glimel (AU, HK);",
"     </li>",
"     <li>",
"      Glimide (MY);",
"     </li>",
"     <li>",
"      Glisulin (KP);",
"     </li>",
"     <li>",
"      Gluben (IL);",
"     </li>",
"     <li>",
"      Glucal (MX);",
"     </li>",
"     <li>",
"      Glucinex (CO);",
"     </li>",
"     <li>",
"      Glucobene (HU);",
"     </li>",
"     <li>",
"      Glucomid (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Gluconic (ID);",
"     </li>",
"     <li>",
"      Glulo (ID);",
"     </li>",
"     <li>",
"      Gluzo (TH);",
"     </li>",
"     <li>",
"      Glycomin (ZA);",
"     </li>",
"     <li>",
"      Hemi-Daonil (AR, FR, MA);",
"     </li>",
"     <li>",
"      Lodulce (PH);",
"     </li>",
"     <li>",
"      Maninil (BG, EE);",
"     </li>",
"     <li>",
"      Manoglucon (TH);",
"     </li>",
"     <li>",
"      Melix (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Miglucan (FR);",
"     </li>",
"     <li>",
"      Norboral (DO, GT, HN, MX, NI, SV);",
"     </li>",
"     <li>",
"      Norglicem (ES);",
"     </li>",
"     <li>",
"      Orabetic (PH);",
"     </li>",
"     <li>",
"      Padonil (ID);",
"     </li>",
"     <li>",
"      Pira (AR);",
"     </li>",
"     <li>",
"      Renabetic (ID);",
"     </li>",
"     <li>",
"      Semi-Daonil (AE, AR, AU, BH, CH, CY, EG, GB, IE, IQ, IR, JO, KW, LB, LY, MA, OM, PT, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Semi-Euglucon (AR, AT, AU, NZ);",
"     </li>",
"     <li>",
"      Sentionyl (PH);",
"     </li>",
"     <li>",
"      Sugril (TH);",
"     </li>",
"     <li>",
"      Xeltic (HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Serum insulin levels begin to increase 15-60 minutes after a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &le;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Significant within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 9-10 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: &gt;99% primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms metabolites (weakly active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Variable among oral dosage forms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Dia&beta;eta&reg;: 10 hours; Glynase&reg; PresTab&reg;: ~4 hours; may be prolonged with renal or hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Adults: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (50%) and urine (50%) as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin, Clinical Management Guidelines for Obstetrician-Gynecologists, Number 60, March 2005,  &ldquo;Pregestational Diabetes Mellitus,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(3):675-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/15738045/pubmed\" id=\"15738045\" target=\"_blank\">",
"        15738045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al, &ldquo;Intensive Blood Glucose Control and Vascular Outcomes in Patients With Type 2 Diabetes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(24):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/18539916/pubmed\" id=\"18539916\" target=\"_blank\">",
"        18539916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Study of the Effects of Hypoglycemia Agents on Vascular Complications in Patients With Adult-onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated With Tolbutamide. The University Group Diabetes Program,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1976, 25(12):1129-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/992232/pubmed\" id=\"992232\" target=\"_blank\">",
"        992232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brodows RG, &ldquo;Benefits and Risks With Glyburide and Glipizide in Elderly NIDDM Patients,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 1992, 15(1):75-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/1737544/pubmed\" id=\"1737544\" target=\"_blank\">",
"        1737544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):854-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/9742977/pubmed\" id=\"9742977\" target=\"_blank\">",
"        9742977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elliott BD, Schenker S, Langer O, et al, &ldquo;Comparative Placental Transport of Oral Hypoglycemic Agents in Humans: A Model of Human Placental Drug Transfer,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1994, 171(3):653-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/8092211/pubmed\" id=\"8092211\" target=\"_blank\">",
"        8092211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feig DS, Briggs GG, Kraemer JM, et al, &ldquo;Transfer of Glyburide and Glipizide Into Breast Milk,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(8):1851-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/16043722/pubmed\" id=\"16043722\" target=\"_blank\">",
"        16043722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gabbe SG and Graves CR, &ldquo;Management of Diabetes Mellitus Complicating Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2003, 102(4):857-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/14551019/pubmed\" id=\"14551019\" target=\"_blank\">",
"        14551019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/9935017/pubmed\" id=\"9935017\" target=\"_blank\">",
"        9935017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gavin JR 3rd, &ldquo;Glyburide: New Insights Into Its Effects on the Beta Cell and Beyond - Introduction,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1990, 89(2A):1S-2S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/2117383/pubmed\" id=\"2117383\" target=\"_blank\">",
"        2117383",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson GF, Ramos GA, Ching JY, et al, &ldquo;Comparison of Glyburide and Insulin for the Management of Gestational Diabetes in a Large Managed Care Organization,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      ,  2005, 193(1):118-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/16021069/pubmed\" id=\"16021069\" target=\"_blank\">",
"        16021069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klamann A, Sarfert P, Launhardt V, et al, &ldquo;Myocardial Infarction in Diabetic vs Nondiabetic Subjects. Survival and Infarct Size Following Therapy With Sulfonylureas (Glibenclamide),&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2000, 21(3):220-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/10639304/pubmed\" id=\"10639304\" target=\"_blank\">",
"        10639304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langer O, Conway D, Berkus M, et al, &ldquo;A Comparison of Glyburide and Insulin in Women With Gestational Diabetes Mellitus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(16):1134-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/11036118/pubmed\" id=\"11036118\" target=\"_blank\">",
"        11036118",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langer O, Yogev Y, Xenakis EM, et al, \"Insulin and Glyburide Therapy: Dosage, Severity Level of Gestational Diabetes, and Pregnancy Outcome,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2005, 192(1):134-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/15672015/pubmed\" id=\"15672015\" target=\"_blank\">",
"        15672015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meinert CL, Knatterud GL, Prout TE, et al, &ldquo;A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset Diabetes. II. Mortality Results,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1970, 19:789-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/4926376/pubmed\" id=\"4926376\" target=\"_blank\">",
"        4926376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nadel HL, &ldquo;Formulary Conversion From Glipizide to Glyburide: A Cost-Minimization Analysis,&rdquo;",
"      <i>",
"       Hosp Pharm",
"      </i>",
"      , 1995, 30(6):467-9, 472-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/10142848/pubmed\" id=\"10142848\" target=\"_blank\">",
"        10142848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nataas OB and Nesthus I, &ldquo;Immune Haemolytic Anaemia Induced by Glibenclamide in Selective IgA Deficiency,&rdquo;",
"      <i>",
"       Br Med J (Clin Res Ed)",
"      </i>",
"      , 1987, 295(6594):366-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/3115451/pubmed\" id=\"3115451\" target=\"_blank\">",
"        3115451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Keefe JH, Blackstone EH, Sergeant P, et al, &ldquo;The Optimal Mode of Coronary Revascularization for Diabetics. A Risk-Adjusted Long-Term Study Comparing Coronary Angioplasty and Coronary Bypass Surgery,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1998, 19(11):1696-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/9857923/pubmed\" id=\"9857923\" target=\"_blank\">",
"        9857923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearson JG, &ldquo;Pharmacokinetics of Glyburide,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1985, 79(3B):67-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/3931464/pubmed\" id=\"3931464\" target=\"_blank\">",
"        3931464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenstock J, Corrao PJ, Goldberg RB, et al, &ldquo;Diabetes Control in the Elderly: A Randomized, Comparative Study of Glyburide Versus Glipizide in Noninsulin-Dependent Diabetes Mellitus,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1993, 15(6):1031-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/8111800/pubmed\" id=\"8111800\" target=\"_blank\">",
"        8111800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwinghammer TL, Antal EJ, Kubacka RT, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Glyburide in Young and Elderly Nondiabetic Adults,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1991, 10(7):532-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/1907234/pubmed\" id=\"1907234\" target=\"_blank\">",
"        1907234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sillence DO and Court JM, &ldquo;Letter: Glibenclamide-Induced Hypoglycemia,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1975, 3(5981):490-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/808247/pubmed\" id=\"808247\" target=\"_blank\">",
"        808247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sonnenblick M and Shilo S, &ldquo;Glibenclamide Induced Prolonged Hypoglycaemia,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1986, 15(3):185-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/3090865/pubmed\" id=\"3090865\" target=\"_blank\">",
"        3090865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study (UKPDS) Group, \"Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33),\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/6/29800/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8494 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29800=[""].join("\n");
var outline_f29_6_29800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176698\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176699\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176748\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176703\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176704\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176705\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176706\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176673\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176659\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176678\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176677\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176745\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176756\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176746\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176681\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176663\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176743\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176668\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176694\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176669\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176684\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176710\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699343\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176685\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176683\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176671\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176674\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176686\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176662\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176680\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/38/15973?source=related_link\">",
"      Glyburide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/22/37222?source=related_link\">",
"      Glyburide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_6_29801="Palliative care: Benefits, services, and models of care";
var content_f29_6_29801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Palliative care: Benefits, services, and models of care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/6/29801/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/6/29801/contributors\">",
"     Diane E Meier, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/6/29801/contributors\">",
"     Elizabeth McCormick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/6/29801/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/6/29801/contributors\">",
"     Claudia Bausewein, PhD, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/6/29801/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/6/29801/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/6/29801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H549034646\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients and their families facing serious illness.&nbsp;",
"   </p>",
"   <p>",
"    The primary tenets of palliative care are symptom management; establishing goals of care that are in keeping with the patient&rsquo;s values and preferences; consistent and sustained communication between the patient and all those involved in his or her care; psychosocial, spiritual, and practical support both to patients and their family caregivers; and coordination across sites of care.",
"   </p>",
"   <p>",
"    Palliative care aims to relieve suffering in all stages of disease and is not limited to end of life care. Palliative services, including setting patient-centered achievable goals for medical care and aggressive symptom management, should be routinely offered alongside curative and disease-modifying treatments for patients with serious illnesses.",
"   </p>",
"   <p>",
"    The traditional model of medical care has been dichotomous, with curative or disease-modifying treatment offered initially and comfort care provided only",
"    <span class=\"nowrap\">",
"     when/if",
"    </span>",
"    these measures fail (",
"    <a class=\"graphic graphic_algorithm graphicRef64252 \" href=\"mobipreview.htm?42/14/43246\">",
"     algorithm 1",
"    </a>",
"    ). However, many illness situations and personal goals do not lend themselves well to such dichotomous service models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/1\">",
"     1",
"    </a>",
"    ]. For example, heart failure is characterized by stable disease punctuated by acute exacerbations often requiring hospitalization (",
"    <a class=\"graphic graphic_figure graphicRef72831 \" href=\"mobipreview.htm?7/50/7982\">",
"     figure 1",
"    </a>",
"    ). During these exacerbations, life-prolonging treatments that also improve symptom burden are administered. Within an integrated model of medical care, palliative care is provided at the same time as curative or life-prolonging treatments (",
"    <a class=\"graphic graphic_algorithm graphicRef64252 \" href=\"mobipreview.htm?42/14/43246\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hospice and Palliative Medicine is now recognized as a medical subspecialty by the American Board of Medical Specialties, as well as in Canada, England, Ireland, Australia, and New Zealand. Many European countries are also in the process of developing certification for palliative care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinicians who are specifically trained in palliative care provide in-depth pain and symptom management, communication regarding goals of care, and care coordination across settings and over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the definition and benefits of palliative care, outline the types of palliative care services and models of care available for adults, present criteria for a referral to palliative care, and outline the key goals of a palliative care consultation. An overview of evaluation in palliative care, the philosophy and nature of hospice care, and pediatric palliative care are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28058?source=see_link\">",
"     \"Pediatric palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549034653\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of palliative care has evolved over time. From the opening of St. Joseph&rsquo;s Hospice for the Dying in 1905 and St. Christopher&rsquo;s Hospice in 1967 until the 1980s, palliative care was largely delivered through hospice programs. Until recently, palliative care was seen as care provided for people who were not receiving active treatment for cancer, and were in fact dying of their disease. It is now recognized that the principles of palliative care are applicable earlier in the course of any serious illness and that palliative care can and should be provided alongside disease modifying treatment. According to the World Health Organization (WHO) position statement, &ldquo;this change in thinking emerged from a new understanding that problems at the end of life have their origins at an earlier time in the trajectory of disease&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following definitions reflect the modern concept of palliative care:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The WHO defines palliative care as: &ldquo;An approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Centers for Medicare and Medicaid Services (CMS) have endorsed the following definition: &ldquo;Palliative care means patient and family-centered care that optimizes quality of life by anticipating, preventing, and treating suffering. Palliative care throughout the continuum of illness involves addressing physical, intellectual, emotional, social, and spiritual needs and facilitating patient autonomy, access to information, and choice&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Center to Advance Palliative Care defines palliative care as: &ldquo;Specialized medical care for people with serious illnesses&hellip;focused on providing patients with relief from the symptoms, pain and stress of a serious illness &mdash; whatever the diagnosis. The goal is to improve quality of life for both the patient and the family. Palliative care is provided by a team of doctors, nurses and other specialists who work together with a patient&rsquo;s other doctors to provide an extra layer of support. It is appropriate at any age and at any stage in a serious illness and can be provided along with curative treatment&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospice, as defined by the Medicare hospice benefit, is a health care delivery system under which support and services are provided to a patient with a terminal illness where the focus is on comfort rather than curing an illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, hospice can be considered a program that delivers palliative care to patients at the end of life, while palliative care can be appropriately offered to patients at any time along the trajectory of any type of serious illness, even concurrent with restorative, life-prolonging therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/9\">",
"     9",
"    </a>",
"    ]. Hospice is a model of palliative care that is offered to patients at the end of life when curative or life-prolonging therapy is no longer indicated. While all care that is delivered by hospices can be considered palliative care, not all palliative care is delivered in hospices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H914734\">",
"    <span class=\"h1\">",
"     RATIONALE FOR PALLIATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aging of the population, success of high technology medicine at prolonging the lives of those who remain seriously ill, and the increasingly fragmented medical system make it difficult for clinicians to provide the full range of services required by patients with serious illness and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/10\">",
"     10",
"    </a>",
"    ]. A multicenter study of over 9000 seriously ill patients found that pain, dyspnea, anxiety, and depression were common and distressing symptoms among seriously ill patients hospitalized in US tertiary care centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Palliative care strives to assist patients in achieving the following goals, important to the seriously ill patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adequate control of pain and other symptoms",
"     </li>",
"     <li>",
"      Achieve a sense of control",
"     </li>",
"     <li>",
"      Relieve burden on family members and strengthening relationships",
"     </li>",
"     <li>",
"      Gain a realistic understanding of the nature of the illness",
"     </li>",
"     <li>",
"      Understand the pros and cons of available treatment alternatives weighed in context of the patient&rsquo;s goals and values",
"     </li>",
"     <li>",
"      Name decision makers in case of loss of decisional capacity",
"     </li>",
"     <li>",
"      Have financial affairs in order",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple studies have shown that palliative care services improve patients&rsquo; symptoms, allow patients to avoid hospitalization and to remain safely and adequately cared for at home, lead to better patient and family satisfaction, and significantly reduce prolonged grief and posttraumatic stress disorder among bereaved family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. Palliative care also lowers costs and reduces rates of unnecessary hospitalizations, diagnostic and treatment interventions, and nonbeneficial intensive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Particularly when initiated early in the disease course, palliative care also improves clinical and quality of care outcomes, and possibly prolongs survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/22,25-30\">",
"     22,25-30",
"    </a>",
"    ]. In a 2012 systematic review of the evidence regarding the impact of palliative care interventions on outcomes for patients with advanced and serious illness, evidence of benefit was strongest for interventions that targeted pain, and for decision making related to appropriate health care utilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following randomized trials are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a landmark study, patients with newly diagnosed metastatic non&ndash;small cell lung cancer who were randomly assigned to early palliative care integrated with standard oncologic care had a better quality of life (QOL), less depressive symptoms, and longer median survival than did those who were assigned to oncologic care alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/25\">",
"       25",
"      </a>",
"      ]. The ambulatory palliative care assessment in this trial focused on symptom management, patient and family coping, and illness understanding and education (",
"      <a class=\"graphic graphic_table graphicRef61159 \" href=\"mobipreview.htm?8/27/8636\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/32\">",
"       32",
"      </a>",
"      ]. In a later analysis, patients receiving early palliative care received the same number of chemotherapy regimens as did those in the control group but they were less likely to have chemotherapy continued close to death and more likely to enroll in hospice for a longer duration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link&amp;anchor=H619540810#H619540810\">",
"       \"Overview of the treatment of advanced non-small cell lung cancer\", section on 'Palliative care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ENABLE II trial demonstrated higher scores for QOL and mood in patients with any life-limiting cancer (prognosis of approximately one year) who received psychoeducational palliative intervention in addition to standard care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial demonstrated that comprehensive outpatient palliative care in patients who continue to pursue disease modifying treatment, compared to usual care, improves symptom management and patient satisfaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with late-stage chronic obstructive pulmonary disease and heart failure who were randomly assigned to in-home palliative care, as compared to usual care, reported greater satisfaction with care and were more likely to die at home [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these benefits, there is a need to change the paradigm for management of patients with advanced life threatening diseases, including but not limited to patients with advanced cancer. Care should include an earlier and more thorough assessment of patients&rsquo; options, goals, and preferences, and be tailored throughout the continuum of their illness to include symptom management and attention to quality of life issues in addition to disease-modifying therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/34\">",
"     34",
"    </a>",
"    ]. A provisional clinical opinion from the American Society of Clinical Oncology (ASCO) advised combining standard oncologic care and palliative care early in the course of illness for all patients with metastatic cancer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high symptom burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H914800\">",
"    <span class=\"h1\">",
"     PALLIATIVE CARE SERVICES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549034660\">",
"    <span class=\"h2\">",
"     Treatment of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary role of palliative care is the relief of pain and other physical, psychological, and emotional symptoms. A meta-analysis of 19 studies concluded that palliative care and hospice teams improved patients&rsquo; pain and other symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with advanced diseases such as dementia may be at substantial risk for undetected or undertreated pain. One study of patients with pain from a hip fracture demonstrated markedly lower analgesic dosing in dementia as compared to cognitively intact patients both pre- and postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/36\">",
"     36",
"    </a>",
"    ]. Pain is a potent precipitant of delirium, and adequacy of pain management is associated with significantly reduced risks of this common and serious hospital complication. Palliative care interventions can improve the management of pain and other symptoms in patients such as these [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This was shown in a study of 592 patients who received a palliative care consultation, in which 87 percent had an improvement in pain or other symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Principles of pain management for adults with cancer, end stage renal disease, and terminal heart failure are addressed in detail elsewhere, as is an overview of symptom control in the terminally ill cancer patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12890?source=see_link\">",
"     \"Pain assessment and management in the last weeks of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36694?source=see_link\">",
"     \"Palliative care: End-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link\">",
"     \"End of life considerations for heart failure patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549034667\">",
"    <span class=\"h2\">",
"     Establishing goals of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goals of care that are clear to clinicians, patients, and families are essential to the provision of appropriate and beneficial medical care. Communication is at the core of establishing goals of care, yet studies have shown that patients are not satisfied with their experiences communicating with clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/13,38\">",
"     13,38",
"    </a>",
"    ] and a concern of family members of persons who died in hospital is not enough time talking with their doctors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/39\">",
"     39",
"    </a>",
"    ]. In the SUPPORT trial, only 47 percent of clinicians caring for adults who were hospitalized with one or more of nine life-threatening diagnoses knew their patients&rsquo; preferences for resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/11\">",
"     11",
"    </a>",
"    ]. Palliative care providers are trained in the communication skills necessary to negotiate goals of care based upon the patient&rsquo;s values and wishes, and to ensure that the care provided is concordant with these goals. Aspects of advance care planning are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=see_link&amp;anchor=H5#H5\">",
"     \"Ethical issues near the end of life\", section on 'Advance care planning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549034674\">",
"    <span class=\"h2\">",
"     Psychosocial support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial, spiritual, and bereavement support are key elements of palliative care. Most programs utilize an interdisciplinary team that may include social workers, chaplains, psychiatrists, psychologists,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bereavement counselors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link\">",
"     \"Grief and bereavement\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=see_link\">",
"     \"Psychosocial issues at the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychological distress, and depression in particular, is prevalent in patients with advanced illnesses. Depression is associated with higher utilization of healthcare services as well as significantly increased mortality rates. Depression, with a prevalence rate of 15 to 60 percent in patients with a terminal illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/40\">",
"     40",
"    </a>",
"    ], is mistakenly but widely felt to be a normal concomitant of illness by health professionals, leading to underdiagnosis and undertreatment. Patients with advanced and chronic disease are as likely to benefit from antidepressant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/41\">",
"     41",
"    </a>",
"    ] and supporting psychotherapy and counseling as other populations. Depression may be due to physical symptoms, stress of prolonged illness, existential distress, or concern for family members. Untreated depression is associated with decreased functional capacity, poorer quality of life, and a desire for hastened death. Studies have shown that treatment of physical symptoms can improve depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=see_link\">",
"     \"Assessment and management of depression in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another key element of palliative care is attending to the needs of family members and caregivers. Studies have shown that most caregivers of hospitalized patients sustain mild to moderate stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/42\">",
"     42",
"    </a>",
"    ]. Caregivers who report emotional strain are at substantially higher risk for death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/43\">",
"     43",
"    </a>",
"    ]. Successful palliative care interventions require attention to the needs of both the patient and the constellation of family members and caregivers surrounding them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complicated grief in survivors has been identified as a distinct disorder that results in severe debilitation and negative health consequences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link&amp;anchor=H14#H14\">",
"     \"Grief and bereavement\", section on 'Treatment of complicated or prolonged grief'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spiritual care is a core domain of palliative care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/45\">",
"     45",
"    </a>",
"    ]. Spirituality plays an important role in coping with serious or terminal illnesses; spiritual distress is highly correlated with a desire for a hastened death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41208?source=see_link&amp;anchor=H2#H2\">",
"     \"Religion, spirituality, and end of life care\", section on 'Religion and spirituality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies indicate that the majority of patients want their health care professionals to ask about spiritual or religious beliefs if they became gravely ill and that they benefit from discussions of these issues with their physicians and from the provision of spiritual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/46\">",
"     46",
"    </a>",
"    ]. Guidelines for interprofessional spiritual care as well as an implementation model for spiritual care have been developed by a consensus conference of experts in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41208?source=see_link&amp;anchor=H6#H6\">",
"     \"Religion, spirituality, and end of life care\", section on 'Assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549034681\">",
"    <span class=\"h2\">",
"     Coordination of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seriously ill patients and their families face major challenges in navigating and understanding their care plan(s) within a complex and fragmented medical system requiring negotiation between multiple settings, specialists, and diagnostic and treatment interventions. Palliative care programs, because of their interdisciplinary approach, assist patients and families to understand and regain control over their care plans and to receive further care in the setting most appropriate to their needs and resources. Appropriate settings may include home care, nursing homes, hospice care, and other inpatient facilities.",
"   </p>",
"   <p>",
"    Programs that provide coordinated care and transition management, such as the Program of All-Inclusive Care for the Elderly (PACE) or the Care Transitions Intervention (CTI), decrease admissions to nursing homes and hospitals and increase rates of advance directives resulting in care matched to patient-determined goals for care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549034688\">",
"    <span class=\"h1\">",
"     MODELS OF PALLIATIVE CARE DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care services can be provided in the hospital, ambulatory setting, or at home. Palliative care services provided by physicians",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced practice nurses in the United States are reimbursed by government and commercial insurance vehicles. Services may be delivered under the specifications of hospice, if the patient has a prognosis of six months or less and is willing to focus care on palliative and comfort-oriented services as opposed to life prolonging treatments. The hospice model is covered by most payers including Medicare, Medicaid, and commercial insurers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link&amp;anchor=H691111#H691111\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\", section on 'Structure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hospital palliative care programs include palliative care consultation teams and dedicated inpatient palliative care units. Non-hospital palliative care programs include ambulatory, office- and home-based palliative care programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549034695\">",
"    <span class=\"h2\">",
"     Hospital-based palliative care programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital palliative care programs in the United States developed from national efforts to improve physical, psychosocial, and spiritual suffering of patients and families who are hospitalized with serious illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/51\">",
"     51",
"    </a>",
"    ]. The number of hospital-based palliative care programs has increased rapidly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/52\">",
"     52",
"    </a>",
"    ] and, as of 2011, programs were in place at more than 63 percent of US hospitals with more than 50 beds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Models of hospital based palliative care services include palliative care consult services and dedicated palliative care units.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most palliative care consultation teams are interdisciplinary and consist of physicians (including generalists and specialists, as well as psychiatrists), nurse practitioners, social workers, psychologists, chaplains, pharmacists, and volunteers. The palliative care team provides expert pain and symptom management, education and communication about achievable goals for care, support for decisions matched to patient and family goals, psychosocial support, and coordination of care. The goal of the consultation service is to support the referring clinician. Typically, the consultation team provides recommendations to the primary attending physician (",
"      <a class=\"graphic graphic_table graphicRef87191 \" href=\"mobipreview.htm?18/63/19451\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In inpatient palliative care units, palliative care providers either may assume primary responsibility for patients or continue in a consulting mode, as desired by the primary physician. Transfer to an inpatient palliative care unit is most appropriate for the following indications: patients who have difficult-to-control symptoms; medical needs that cannot be optimally managed in another setting; distressed families in need of a higher level of support; need for transfer out of a critical care setting; patients who are imminently dying. A high-volume palliative care unit may reduce in-hospital care costs by matching treatments provided to patient and family-determined goals for medical care. In one study, a dedicated palliative care unit reduced daily hospital costs by 74 percent compared to usual care patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A few studies have compared outcomes with different palliative care models. In a phone survey of US Veterans Administration (VA) medical centers that offered both models of inpatient care, family members of patients in a palliative care unit were significantly more likely to report excellent care in the last month of life when compared with families of patients who received a palliative care consultation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/20\">",
"     20",
"    </a>",
"    ]. The palliative care unit group also scored highest in three of four process measures (do not resuscitate order at the time of death, documented chaplain visit, and bereavement contact after the patient&rsquo;s death). In another study comparing patients admitted to a palliative care unit with those receiving palliative care consultation services, patients in the dedicated unit had significantly worse performance scores, required greater complexity of care, and were more likely to die [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/54\">",
"     54",
"    </a>",
"    ]. Self-rated satisfaction for dying patients was higher for patients in the palliative care unit.",
"   </p>",
"   <p>",
"    The optimal palliative care model for an individual institution is determined by weighing several factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/55\">",
"     55",
"    </a>",
"    ], and coexistence of both models within an institution is ideal, when the institution is large enough to support the required resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/54\">",
"     54",
"    </a>",
"    ]. A dedicated unit offers direct control over implementation of the palliative care team&rsquo;s recommendations, the presence of a skilled interdisciplinary staff, and a care setting that is designed to meet the needs of seriously ill patients. A consultative team, on the other hand, is less resource intensive, able to deliver care to many more patients and their families, and may be able to promote the importance of the palliative care approach to a wider audience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549034702\">",
"    <span class=\"h2\">",
"     Non-hospital palliative care services",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory palliative care programs provide important continuity of care for patients who are discharged from the hospital after being seen by an inpatient palliative care consultation service. In addition, ambulatory palliative care providers can act as consultants for patients who are not hospitalized but who have complex or advanced illnesses, symptom distress, and difficulty managing complex treatment regimens. Ambulatory palliative care teams provide pain and symptom management, psychosocial support, and coordination of home care needs. Often, patients receive ambulatory palliative care in conjunction with life prolonging therapy.",
"   </p>",
"   <p>",
"    When initiated early in the disease course, ambulatory palliative care improves clinical and quality of care outcomes, including better survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Home-based palliative care services can be provided by clinicians who make home visits or certified home health agency programs that provide care in the home. These programs are particularly useful when patients do not qualify for hospice but have serious illnesses and are essentially homebound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51425789\">",
"    <span class=\"h2\">",
"     Hospice model of palliative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospice is a model for delivery of palliative care for patients at the end of life when curative or life-prolonging therapy is no longer beneficial. The modern concept of hospice, as established by Dr. Cicely Saunders of St. Christopher&rsquo;s Hospice in England in 1967, has now spread throughout the world.",
"   </p>",
"   <p>",
"    The hospice model requires interdisciplinary team care. Hospice care can be provided in homes, hospitals, nursing homes, and freestanding hospice inpatient facilities. Functionally dependent or cognitively impaired patients who pose high and prolonged burdens of family caregiving are more likely to be referred for inpatient hospice than home care compared to other hospice populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The philosophy of hospice care, services provided by hospice, and its advantages and disadvantages, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H914876\">",
"    <span class=\"h1\">",
"     IDENTIFYING PATIENTS APPROPRIATE FOR A PALLIATIVE CARE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2011 consensus statement from the Center to Advance Palliative Care proposed criteria for identifying patients in need of palliative care assessment in the hospital setting (",
"    <a class=\"graphic graphic_table graphicRef76969 \" href=\"mobipreview.htm?30/62/31724\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/58\">",
"     58",
"    </a>",
"    ]. The palliative care needs of patients meeting one or more of these criteria should be addressed by their primary medical team, with consultation by palliative care specialists to assist with time-intensive complex decision-making regarding goals of care and treatment options, to make recommendations regarding pain and symptom management, and to help address complicated psychosocial, spiritual, and social issues.",
"   </p>",
"   <p>",
"    While criteria for palliative care assessments are not available for patients in the outpatient setting, the primary care clinician should consider consultation to a palliative care specialist team for patients who have poorly controlled symptoms, frequent visits to the emergency room, one or more hospital admissions in 30 days, a prolonged hospitalization,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a prolonged ICU stay. An affirmative answer by the primary care clinician to the consideration: &ldquo;Would you be surprised if the patient died within 12 months, or did not live to adulthood&rdquo;",
"    <em>",
"    </em>",
"    might also guide the identification of patients who would benefit from a palliative care assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H914884\">",
"    <span class=\"h2\">",
"     Initial consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial components of a palliative care assessment are illustrated in a table (",
"    <a class=\"graphic graphic_table graphicRef51669 \" href=\"mobipreview.htm?36/16/37131\">",
"     table 4",
"    </a>",
"    ) and should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessing for pain and other symptoms",
"     </li>",
"     <li>",
"      Determining the patient and families&rsquo; understanding of the illness, prognosis and treatment options",
"     </li>",
"     <li>",
"      Assessing patient and family psychosocial and spiritual support needs",
"     </li>",
"     <li>",
"      Identifying patient centered goals",
"     </li>",
"     <li>",
"      Discussing treatment preferences and coordinating care between providers and settings",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H914970\">",
"    <span class=\"h1\">",
"     PERCEPTIONS OF PALLIATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a public opinion poll conducted in 2011 by the Center to Advance Palliative Care and the American Cancer Society, over 90 percent of those polled wanted palliative care for themselves or a loved one facing a serious illness, agreed that it is important for patients with serious illness and their loved ones to be educated about palliative care, and felt that it was important that palliative care services be available at all hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/59\">",
"     59",
"    </a>",
"    ]. Barriers to palliative care utilization were identified, including patient and family lack of awareness of palliative care services and tendency of clinicians to equate palliative care with end of life care. In addition, the study explored how the language used to define palliative care impacted the perceptions of consumers about palliative care. Definitions that had a significant positive impact include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Palliative care is specialized medical care for people with serious illnesses. This type of care is focused on providing patients with relief from the symptoms, pain, and stress of a serious illness &mdash; whatever the diagnosis.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;The goal is to improve quality of life for both the patient and the family. Palliative care is provided by a team of doctors, nurses, and other specialists who work with a patient&rsquo;s other doctors to provide an extra layer of support. Palliative care is appropriate at any age and at any stage in a serious illness, and can be provided together with curative treatment&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A poll completed of physicians in the US found that while the majority of the 500 physicians surveyed (96 percent) agreed that &ldquo;it is more important to enhance the quality of life for seriously ill patients&rdquo; than &ldquo;to extend life through every medical intervention possible,&rdquo; physicians acknowledged concerns about incorporating palliative care, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concern that introducing palliative care could interfere with therapy directed at extending life as long as possible (42 percent)",
"     </li>",
"     <li>",
"      Inadequate patient resources (78 percent)",
"     </li>",
"     <li>",
"      Issues related to reimbursement (82 percent)",
"     </li>",
"     <li>",
"      Shortage of palliative care physicians and services (78 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, this survey identified gaps in the education of physicians in palliative care during medical school based on physician age. The majority (73 percent) of physicians age 39 or younger reported exposure to palliative care during medical school, while only 36 percent of those ages 40 to 49, 23 percent of those ages 50 to 59, and 6 percent of those age 60 or older were exposed to palliative care during training.",
"   </p>",
"   <p>",
"    While the recognized need for and benefits of palliative care remain largely unequivocal, the specific palliative care needs and goals of individual patients are more challenging to identify [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/61\">",
"     61",
"    </a>",
"    ]. For example, the legislative history and design of the Medicare hospice benefit is targeted towards patients with a preference for home care and an almost exclusive focus on comfort measures. This reflects the tendency among clinicians to predefine the desirable attributes of an effective palliative care program. While a preference for home-based comfort measures may be common, it is not universal. One study suggests that as few as 35 percent of patients want to die at home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/62\">",
"     62",
"    </a>",
"    ]. Furthermore, as many as 48 percent of patients in this study cohort considered access to all available treatments as an important aspect of palliative care at the end of life, regardless of the chance of recovery, compared to only 5 to 7 percent of health care providers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, patients and their health care providers may also differ in how they rank the importance of common symptoms and care needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/63\">",
"     63",
"    </a>",
"    ]. In one study, patients with inoperable lung cancer self-reported a number of distressing problems that were not included in comprehensive symptoms questionnaires available for clinical care and research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/64\">",
"     64",
"    </a>",
"    ]. Studies have also shown that patients with inoperable lung cancer differed substantially from their physicians with regard to factors and priorities impacting treatment decisions for the malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/65\">",
"     65",
"    </a>",
"    ]. Even symptoms that seem universally undesirable (eg, pain) are subject to individual interpretations and varying treatment preferences. One study found that less than one-third of patients (29 percent) who reported pain desired no additional analgesic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2010 review of guidelines and policies from the US, UK, Canada, and Australia confirmed the paucity of uniform sets of fixed patient expectations and clinical standards for palliative care and found that &ldquo;palliative care staff have to continuously adapt their model of caring to the specific needs and values of each patient&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/67\">",
"     67",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    These findings suggest that individual preferences and many attributes of quality palliative care for specific patients can be revealed only through careful individual assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A helpful resource for patients, families, and clinicians seeking information about palliative care services, as well as a directory of palliative care specialists in the United States, is available through the organization",
"    <a class=\"external\" href=\"file://getpalliativecare.org/\">",
"     Get Palliative Care",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       \"Patient information: Medical care during advanced illness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=see_link\">",
"       \"Patient information: Advance directives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51425731\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palliative care is an interdisciplinary specialty that is focused on preventing and relieving suffering, and supporting the best possible quality of life for patients and their families facing serious illness. Clinicians who are specialty trained in palliative care provide in depth pain and symptom management, communication regarding goals of care, and coordinated care across settings and over time. (See",
"      <a class=\"local\" href=\"#H549034646\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palliative care aims to relieve suffering in all stages of disease and can be provided at the same time as curative or life-prolonging treatments (",
"      <a class=\"graphic graphic_algorithm graphicRef64252 \" href=\"mobipreview.htm?42/14/43246\">",
"       algorithm 1",
"      </a>",
"      ). When initiated early in the disease course, palliative care has been shown to improve clinical, quality of care and survival outcomes. Hospice is a health care delivery system under which support and services are provided to a patient with a terminal illness where the focus is on comfort rather than curing an illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29801/abstract/8\">",
"       8",
"      </a>",
"      ]. Thus, hospice can be considered a program that delivers palliative care to patients at the end of life, while palliative care can be appropriately offered to patients at any time along the trajectory of any type of serious illness. (See",
"      <a class=\"local\" href=\"#H549034653\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A primary role of palliative care is the relief of pain and other emotional and physical symptoms. Other key services are establishing goals of care, psychosocial, spiritual, and bereavement support, and coordination of care. (See",
"      <a class=\"local\" href=\"#H914734\">",
"       'Rationale for palliative care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palliative care services can be provided in the hospital, ambulatory setting, or at home. Hospital-based palliative care programs may entail a dedicated unit",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an interdisciplinary consultation service; the palliative care consultation service is the most common model. Hospice care can be provided in homes, hospitals, nursing homes, and freestanding hospice inpatient facilities. (See",
"      <a class=\"local\" href=\"#H549034688\">",
"       'Models of palliative care delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A 2011 consensus statement proposed criteria for identifying patients in need of palliative care assessment in the hospital setting (",
"      <a class=\"graphic graphic_table graphicRef76969 \" href=\"mobipreview.htm?30/62/31724\">",
"       table 3",
"      </a>",
"      ). While explicit criteria have not been developed for the ambulatory setting, referral for palliative care evaluation is appropriate for patients with poorly controlled symptoms, frequent visits to the emergency room, one or more hospital admissions in 30 days, a prolonged hospitalization, a prolonged ICU stay, or with a prognosis of one year or less. The surprise question: &ldquo;Would you not be surprised if the patient died within 12 months, or did not live to adulthood?&rdquo;",
"      <em>",
"      </em>",
"      can serve as a guide. (See",
"      <a class=\"local\" href=\"#H914876\">",
"       'Identifying patients appropriate for a palliative care assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A palliative care assessment should include a review of symptoms, social and spiritual needs and support, the patient&rsquo;s understanding of illness, as well as discussions of advanced directives and patient centered goals (",
"      <a class=\"graphic graphic_table graphicRef51669 \" href=\"mobipreview.htm?36/16/37131\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H914884\">",
"       'Initial consultation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/1\">",
"      Lynn J. Living long in fragile health: the new demographics shape end of life care. Hastings Cent Rep 2005; Spec No:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/2\">",
"      Centeno C, Noguera A, Lynch T, Clark D. Official certification of doctors working in palliative medicine in Europe: data from an EAPC study in 52 European countries. Palliat Med 2007; 21:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/3\">",
"      Morrison RS, Meier DE. Clinical practice. Palliative care. N Engl J Med 2004; 350:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/4\">",
"      Sep&uacute;lveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization's global perspective. J Pain Symptom Manage 2002; 24:91.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO) definition of palliative care, available online at file://www.who.int/cancer/palliative/definition/en (Accessed on January 07, 2011).",
"    </li>",
"    <li>",
"     Federal Register 2008 - 73 FR 32204, June 5, 2008.",
"    </li>",
"    <li>",
"     Center to Advance Palliative Care (CAPC) definition of palliative care. file://www.capc.org/building-a-hospital-based-palliative-care-program/case/definingpc (Accessed on September 04, 2012).",
"    </li>",
"    <li>",
"     Medicare Hospice Benefits. Centers for Medicare and Medicaid Services 2010. file://www.medicare.gov/Publications/Pubs/pdf/02154.pdf. Accessed November 21, 2010. (Accessed on January 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/9\">",
"      Teno JM, Connor SR. Referring a patient and family to high-quality palliative care at the close of life: \"We met a new personality... with this level of compassion and empathy\". JAMA 2009; 301:651.",
"     </a>",
"    </li>",
"    <li>",
"     Approaching death: improving care at the end of life, Field, MJ, Cassel, CK (Eds), National Academy Press, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/11\">",
"      A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995; 274:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/12\">",
"      Desbiens NA, Mueller-Rizner N, Connors AF Jr, et al. The symptom burden of seriously ill hospitalized patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcome and Risks of Treatment. J Pain Symptom Manage 1999; 17:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/13\">",
"      Singer PA, Martin DK, Kelner M. Quality end-of-life care: patients' perspectives. JAMA 1999; 281:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/14\">",
"      Steinhauser KE, Christakis NA, Clipp EC, et al. Preparing for the end of life: preferences of patients, families, physicians, and other care providers. J Pain Symptom Manage 2001; 22:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/15\">",
"      Elsayem A, Swint K, Fisch MJ, et al. Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 2004; 22:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/16\">",
"      Smith TJ, Coyne P, Cassel B, et al. A high-volume specialist palliative care unit and team may reduce in-hospital end-of-life care costs. J Palliat Med 2003; 6:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/17\">",
"      Higginson IJ, Finlay I, Goodwin DM, et al. Do hospital-based palliative teams improve care for patients or families at the end of life? J Pain Symptom Manage 2002; 23:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/18\">",
"      Higginson IJ, Finlay IG, Goodwin DM, et al. Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers? J Pain Symptom Manage 2003; 25:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/19\">",
"      Manfredi PL, Morrison RS, Morris J, et al. Palliative care consultations: how do they impact the care of hospitalized patients? J Pain Symptom Manage 2000; 20:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/20\">",
"      Casarett D, Johnson M, Smith D, Richardson D. The optimal delivery of palliative care: a national comparison of the outcomes of consultation teams vs inpatient units. Arch Intern Med 2011; 171:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/21\">",
"      Morrison RS, Penrod JD, Cassel JB, et al. Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med 2008; 168:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/22\">",
"      Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009; 302:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/23\">",
"      Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008; 300:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/24\">",
"      Wright AA, Keating NL, Balboni TA, et al. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol 2010; 28:4457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/25\">",
"      Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/26\">",
"      Rabow MW, Dibble SL, Pantilat SZ, McPhee SJ. The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med 2004; 164:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/27\">",
"      Rabow MW, Schanche K, Petersen J, et al. Patient perceptions of an outpatient palliative care intervention: \"It had been on my mind before, but I did not know how to start talking about death...\". J Pain Symptom Manage 2003; 26:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/28\">",
"      Brumley R, Enguidanos S, Jamison P, et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc 2007; 55:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/29\">",
"      Casarett D, Pickard A, Bailey FA, et al. Do palliative consultations improve patient outcomes? J Am Geriatr Soc 2008; 56:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/30\">",
"      Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative care team: a randomized control trial. J Palliat Med 2008; 11:180.",
"     </a>",
"    </li>",
"    <li>",
"     Improving health care and palliative care for advanced and serious illness. Closing the quality gap. Agency for Healthcare Research and Quality. file://effectivehealthcare.ahrq.gov/ehc/products/325/1303/EvidReport208_CQGPalliativeCare_FinalReport_20121024.pdf (Accessed on January 16, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/32\">",
"      Jacobsen J, Jackson V, Dahlin C, et al. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer. J Palliat Med 2011; 14:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/33\">",
"      Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 2012; 30:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/34\">",
"      Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011; 29:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/35\">",
"      Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 2012; 30:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/36\">",
"      Morrison RS, Siu AL. A comparison of pain and its treatment in advanced dementia and cognitively intact patients with hip fracture. J Pain Symptom Manage 2000; 19:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/37\">",
"      O'Mahony S, Blank AE, Zallman L, Selwyn PA. The benefits of a hospital-based inpatient palliative care consultation service: preliminary outcome data. J Palliat Med 2005; 8:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/38\">",
"      Quill TE. Perspectives on care at the close of life. Initiating end-of-life discussions with seriously ill patients: addressing the \"elephant in the room\". JAMA 2000; 284:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/39\">",
"      Teno JM, Clarridge BR, Casey V, et al. Family perspectives on end-of-life care at the last place of care. JAMA 2004; 291:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/40\">",
"      Hotopf M, Chidgey J, Addington-Hall J, Ly KL. Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 2002; 16:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/41\">",
"      Rayner L, Price A, Evans A, et al. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med 2011; 25:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/42\">",
"      Desbiens NA, Mueller-Rizner N, Virnig B, Lynn J. Stress in caregivers of hospitalized oldest-old patients. J Gerontol A Biol Sci Med Sci 2001; 56:M231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/43\">",
"      Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999; 282:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/44\">",
"      O'Hara RE, Hull JG, Lyons KD, et al. Impact on caregiver burden of a patient-focused palliative care intervention for patients with advanced cancer. Palliat Support Care 2010; 8:395.",
"     </a>",
"    </li>",
"    <li>",
"     National Quality Forum: A National Framework and Preferred Practices for Palliative and Hospice Care: A Consensus Report. file://www.qualityforum.org/Publications/2006/12/A_National_Framework_and_Preferred_Practices_for_Palliative_and_Hospice_Care_Quality.aspx (Accessed on September 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/46\">",
"      Ehman JW, Ott BB, Short TH, et al. Do patients want physicians to inquire about their spiritual or religious beliefs if they become gravely ill? Arch Intern Med 1999; 159:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/47\">",
"      Puchalski C, Ferrell B, Virani R, et al. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med 2009; 12:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/48\">",
"      Mukamel DB, Bajorska A, Temkin-Greener H. Health care services utilization at the end of life in a managed care program integrating acute and long-term care. Med Care 2002; 40:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/49\">",
"      Hughes SL, Weaver FM, Giobbie-Hurder A, et al. Effectiveness of team-managed home-based primary care: a randomized multicenter trial. JAMA 2000; 284:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/50\">",
"      Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention: results of a randomized controlled trial. Arch Intern Med 2006; 166:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/51\">",
"      Fischberg D, Meier DE. Palliative care in hospitals. Clin Geriatr Med 2004; 20:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/52\">",
"      Morrison RS, Maroney-Galin C, Kralovec PD, Meier DE. The growth of palliative care programs in United States hospitals. J Palliat Med 2005; 8:1127.",
"     </a>",
"    </li>",
"    <li>",
"     www.capc.org (Accessed on June 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/54\">",
"      Gaertner J, Frechen S, Sladek M, et al. Palliative care consultation service and palliative care unit: why do we need both? Oncologist 2012; 17:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/55\">",
"      Chai E, Meier DE. Identifying the effective components of palliative care: comment on \"The optimal delivery of palliative care\". Arch Intern Med 2011; 171:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/56\">",
"      Smith KL, Ornstein K, Soriano T, et al. A multidisciplinary program for delivering primary care to the underserved urban homebound: looking back, moving forward. J Am Geriatr Soc 2006; 54:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/57\">",
"      Fainsinger RL, Demoissac D, Cole J, et al. Home versus hospice inpatient care: discharge characteristics of palliative care patients in an acute care hospital. J Palliat Care 2000; 16:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/58\">",
"      Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting: a consensus report from the Center to Advance Palliative Care. J Palliat Med 2011; 14:17.",
"     </a>",
"    </li>",
"    <li>",
"     Center to Advance Palliative Care 2011 Public Opinion Research on palliative care. file://www.capc.org/tools-for-palliative-care-programs/marketing/public-opinion-research/2011-public-opinion-research-on-palliative-care.pdf (Accessed on September 04, 2012).",
"    </li>",
"    <li>",
"     The Regence Foundation Living Well at the End of Life Poll Results. file://syndication.nationaljournal.com/communications/NationalJournalRegenceDoctorsToplines.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/61\">",
"      Munday D, Petrova M, Dale J. Exploring preferences for place of death with terminally ill patients: qualitative study of experiences of general practitioners and community nurses in England. BMJ 2009; 339:b2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/62\">",
"      Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000; 284:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/63\">",
"      Snyder CF, Dy SM, Hendricks DE, et al. Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice. Support Care Cancer 2007; 15:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/64\">",
"      Tishelman C, L&ouml;vgren M, Broberger E, et al. Are the most distressing concerns of patients with inoperable lung cancer adequately assessed? A mixed-methods analysis. J Clin Oncol 2010; 28:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/65\">",
"      Silvestri GA, Knittig S, Zoller JS, Nietert PJ. Importance of faith on medical decisions regarding cancer care. J Clin Oncol 2003; 21:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/66\">",
"      Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet 2001; 357:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/67\">",
"      Barazzetti G, Borreani C, Miccinesi G, Toscani F. What \"best practice\" could be in Palliative Care: an analysis of statements on practice and ethics expressed by the main Health Organizations. BMC Palliat Care 2010; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29801/abstract/68\">",
"      Heyland DK, Dodek P, Rocker G, et al. What matters most in end-of-life care: perceptions of seriously ill patients and their family members. CMAJ 2006; 174:627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14240 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29801=[""].join("\n");
var outline_f29_6_29801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H51425731\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549034646\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549034653\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H914734\">",
"      RATIONALE FOR PALLIATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H914800\">",
"      PALLIATIVE CARE SERVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549034660\">",
"      Treatment of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549034667\">",
"      Establishing goals of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549034674\">",
"      Psychosocial support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549034681\">",
"      Coordination of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549034688\">",
"      MODELS OF PALLIATIVE CARE DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549034695\">",
"      Hospital-based palliative care programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549034702\">",
"      Non-hospital palliative care services",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51425789\">",
"      Hospice model of palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H914876\">",
"      IDENTIFYING PATIENTS APPROPRIATE FOR A PALLIATIVE CARE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H914884\">",
"      Initial consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H914970\">",
"      PERCEPTIONS OF PALLIATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51425731\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/14240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14240|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?42/14/43246\" title=\"algorithm 1\">",
"      Healthcare delivery mods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14240|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/50/7982\" title=\"figure 1\">",
"      Disease prog CA vs CD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14240|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/27/8636\" title=\"table 1\">",
"      Components of early ambulatory palliative care consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/63/19451\" title=\"table 2\">",
"      Principles of consultation etiquette",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/62/31724\" title=\"table 3\">",
"      Palliative care assessment at admission criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/16/37131\" title=\"table 4\">",
"      Primary palliative care assessment components",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=related_link\">",
"      End of life considerations for heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/37/12890?source=related_link\">",
"      Pain assessment and management in the last weeks of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36694?source=related_link\">",
"      Palliative care: End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28058?source=related_link\">",
"      Pediatric palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=related_link\">",
"      Psychosocial issues at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41208?source=related_link\">",
"      Religion, spirituality, and end of life care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_6_29802="Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children";
var content_f29_6_29802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/6/29802/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/6/29802/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/6/29802/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/6/29802/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/6/29802/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/6/29802/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/6/29802/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (MRSA,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    minimum inhibitory concentration [MIC] &ge;4",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    has increased in prevalence worldwide as both a healthcare-associated and a community-associated pathogen. Community-associated MRSA most frequently causes skin and soft-tissue infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, it is increasingly associated with invasive infections, particularly pneumonia and musculoskeletal infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increasing proportion of MRSA isolates are resistant to additional antimicrobial agents, which complicates therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/3\">",
"     3",
"    </a>",
"    ]. The identification of",
"    <em>",
"     S. aureus",
"    </em>",
"    strains with intermediate and complete resistance to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    has raised particular concern. Children with infections due to such organisms should be managed in consultation with an expert in infectious diseases.",
"   </p>",
"   <p>",
"    The treatment of invasive infections caused by MRSA,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    -intermediate",
"    <em>",
"     S. aureus",
"    </em>",
"    (VISA), and vancomycin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (VRSA) in children will be reviewed here. The genetic mechanisms responsible for methicillin resistance; the epidemiology, prevention, and control of MRSA infections in children; and the treatment of MRSA skin and soft-tissue infections in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33290?source=see_link\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRSA, VISA, and VRSA infections in adults also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is the treatment of choice for invasive methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) infections in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ]. A variety of other agents have been used in patients who are allergic to or unable to tolerate vancomycin. These include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"     daptomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is a glycopeptide antibiotic that inhibits cell wall synthesis. It is the drug of choice for the treatment of many invasive infections caused by MRSA, given its efficacy, safety profile, and convenient dosing (",
"    <a class=\"graphic graphic_table graphicRef78349 \" href=\"mobipreview.htm?42/2/43053\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. It is also the agent for which there is the most clinical experience in treating a variety of invasive clinical syndromes (eg, pneumonia, endocarditis, meningitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. When vancomycin is used for treatment of serious infections, achieving trough concentrations between 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is recommended by many experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'MRSA infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One or more adjunctive agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    ) have been added to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    when treating life-threatening infections (eg, sepsis, central nervous system infection, endocarditis) (",
"    <a class=\"graphic graphic_table graphicRef78349 \" href=\"mobipreview.htm?42/2/43053\">",
"     table 1",
"    </a>",
"    ) and infections caused by strains intermediately susceptible to vancomycin (",
"    <a class=\"graphic graphic_table graphicRef69174 \" href=\"mobipreview.htm?35/57/36765\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ]. However, there are no data from controlled trials establishing a benefit for combination therapy. The addition of gentamicin may lead to greater nephrotoxicity without any evidence of benefit. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'For critically ill'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'VISA infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    is superior to the available alternatives for the treatment of MRSA, it is less effective than beta-lactams for methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    (MSSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Thus, once results of susceptibility testing are known,",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates that are methicillin- or penicillin-susceptible should be treated with beta-lactams rather than vancomycin (",
"    <a class=\"graphic graphic_table graphicRef57379 \" href=\"mobipreview.htm?43/17/44316\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolates of MRSA with intermediate susceptibility to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    and vancomycin resistance have been reported. Such isolates have been rarely reported in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/14\">",
"     14",
"    </a>",
"    ]. The identification of these strains poses additional therapeutic dilemmas. A greater concern is the increasing identification of",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates that do not respond to vancomycin therapy in vivo but are not vancomycin resistant by",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    minimum inhibitory concentration (MIC) determinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clindamycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    has been effective in the treatment of community-associated MRSA infections in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. It is a drug of choice for MRSA pneumonia, septic arthritis, and osteomyelitis if the isolate is susceptible, the D-test is negative, and blood cultures are negative (",
"    <a class=\"graphic graphic_table graphicRef78349 \" href=\"mobipreview.htm?42/2/43053\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54213 \" href=\"mobipreview.htm?30/31/31217\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Inducible resistance'",
"    </a>",
"    below). Clindamycin is well absorbed orally, so therapy can be completed orally (when clinically appropriate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is also an option for initial empiric therapy for non-life-threatening",
"    <em>",
"     S. aureus",
"    </em>",
"    infection when rates of MRSA colonization and infection in the community are substantial (eg, &gt;10 percent) and the prevalence of clindamycin resistance is low (eg, &lt;10 percent) (",
"    <a class=\"graphic graphic_table graphicRef61437 \" href=\"mobipreview.htm?23/38/24173\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    should not be used for empiric treatment of invasive infections in communities with high rates (eg, &gt;10 percent) of inducible clindamycin resistance, as treatment failures have occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ]. It also should not be used in patients with risk factors for healthcare-associated MRSA (HA-MRSA) since many of these strains are resistant to clindamycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Microbiologic characteristics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Inducible resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    may emerge during therapy in strains of MRSA with the inducible macrolide-lincosamide-streptogramin B (MLS)-resistance mechanism. MRSA isolates with the inducible MLS resistance mechanism appear susceptible to clindamycin and resistant to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    by most standard techniques, but can be detected using the \"D test\" (",
"    <a class=\"graphic graphic_picture graphicRef54213 \" href=\"mobipreview.htm?30/31/31217\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17495?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of antibacterial susceptibility testing\", section on 'D test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is best avoided when the isolates are D-zone positive. This is particularly true if a large inoculum of organisms is expected or antibiotics cannot easily reach the site of a deep infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Linezolid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    is an oxazolidinone antibiotic active against many antibiotic-resistant gram-positive cocci. It inhibits bacterial protein synthesis, thereby preventing formation of the 70S initiation complex. Linezolid is approved by the US Food and Drug Administration (FDA) for use in nosocomial pneumonia and complicated skin infections, including cases caused by MRSA (",
"    <a class=\"graphic graphic_table graphicRef63973 \" href=\"mobipreview.htm?2/60/3020\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/10,29\">",
"     10,29",
"    </a>",
"    ]. It is bacteriostatic for",
"    <em>",
"     S. aureus",
"    </em>",
"    and thus is not routinely recommended for treatment of MRSA bacteremia or catheter-related bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/30\">",
"     30",
"    </a>",
"    ]. Linezolid has not been well studied in the treatment of osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/22\">",
"     22",
"    </a>",
"    ], although one case series in children reported linezolid to be effective in several patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/31\">",
"     31",
"    </a>",
"    ]. Isolated cases of linezolid-resistant MRSA and apparent failures of linezolid to treat or prevent endocarditis in patients with intravascular MRSA infection have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/32-36\">",
"     32-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    is an alternative to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    in children with serious MRSA infections when susceptibility testing has indicated that the isolate is susceptible (",
"    <a class=\"graphic graphic_table graphicRef78349 \" href=\"mobipreview.htm?42/2/43053\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ]. It also can be used, in conjunction with either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    , in children with vancomycin-intermediate",
"    <em>",
"     S. aureus",
"    </em>",
"    (VISA) (",
"    <a class=\"graphic graphic_table graphicRef69174 \" href=\"mobipreview.htm?35/57/36765\">",
"     table 2",
"    </a>",
"    ). Consultation with an expert in infectious diseases is suggested before use of linezolid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Linezolid is well absorbed orally, so therapy can be completed orally (when clinically appropriate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    was equivalent to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    for the treatment of serious MRSA infections in a randomized, open-label trial in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/9\">",
"     9",
"    </a>",
"    ]. Experience with linezolid for the treatment of staphylococcal infections in children is limited, but growing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/10,31,37,38\">",
"     10,31,37,38",
"    </a>",
"    ]. It was equivalent to vancomycin for MRSA in a randomized trial in 321 hospitalized children (0 to 11 years) with gram-positive pneumonia, bacteremia, or complicated skin infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/10\">",
"     10",
"    </a>",
"    ]. The overall clinical cure rates were 79 and 74 percent for linezolid and vancomycin, respectively. Among patients with MRSA, clinical cure rates were 94 and 90 percent, and bacteriologic cure rates were 88 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/38\">",
"     38",
"    </a>",
"    ]. A similarly designed trial in neonates also found linezolid to be well tolerated and as effective as vancomycin in the treatment of resistant gram-positive infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    resistance and linezolid failure have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/33,34,39,40\">",
"     33,34,39,40",
"    </a>",
"    ]. In two case reports, endocarditis developed during treatment for MRSA infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/33\">",
"     33",
"    </a>",
"    ], and relapse of clinical infection occurred in a patient treated with linezolid for the final weeks of endocarditis therapy following echocardiographic resolution of the vegetation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/34\">",
"     34",
"    </a>",
"    ]. An outbreak has also been described in an intensive care setting; reduction of linezolid use and infection control measures were associated with termination of the outbreak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few adverse effects have been reported with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    in children; the most common side effects are rash, nausea, vomiting, and thrombocytopenia (which is more common in adults who receive linezolid for more than 14 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Less common adverse effects include optic neuritis, neuropathy, and metabolic acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/22,45,46\">",
"     22,45,46",
"    </a>",
"    ]. If the duration of therapy is &gt;2 weeks, complete blood count should be monitored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/44,47,48\">",
"     44,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Quinupristin-dalfopristin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"     Quinupristin-dalfopristin",
"    </a>",
"    is a streptogramin antibiotic. It is approved by the US Food and Drug Administration (FDA) for the treatment of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococcal infections and complicated skin infections caused by MSSA in adults and children &gt;16 years of age. It also has activity against MRSA and VISA isolates, although MRSA resistance has been described rarely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/49\">",
"     49",
"    </a>",
"    ]. There may be synergy against MRSA when quinupristin-dalfopristin is combined with beta-lactams, and additive activity when combined with vancomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"     Quinupristin-dalfopristin",
"    </a>",
"    is an alternative to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    in children with serious MRSA infections when susceptibility testing has indicated that the isolate is susceptible (",
"    <a class=\"graphic graphic_table graphicRef78349 \" href=\"mobipreview.htm?42/2/43053\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ]. It also can be used, in conjunction with either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    , in children with VISA (",
"    <a class=\"graphic graphic_table graphicRef69174 \" href=\"mobipreview.htm?35/57/36765\">",
"     table 2",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H21\">",
"     'VISA infections'",
"    </a>",
"    below). Consultation with an expert in infectious diseases is suggested before use of quinupristin-dalfopristin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"     Quinupristin-dalfopristin",
"    </a>",
"    activity against MRSA in adults was demonstrated in a series of 90 patients with MRSA bone, joint, skin, or soft-tissue infections who did not tolerate or had failed",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    therapy; the overall response rate was 71 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/52\">",
"     52",
"    </a>",
"    ]. Experience with quinupristin-dalfopristin in children is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,53\">",
"     4,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    requires central venous access. Adverse effects include hyperbilirubinemia, myalgias, arthralgias, and nausea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Daptomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is a cyclic lipopeptide antibiotic that causes depolarization of the bacterial cell membrane and is bactericidal for",
"    <em>",
"     S. aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/8,54,55\">",
"     8,54,55",
"    </a>",
"    ]. It is approved by the FDA for treatment of patients &gt;18 years of age with complicated skin and skin-structure infections and bacteremia with or without endocarditis due to MRSA and other selected gram-positive pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Daptomycin should not be used for treatment of MRSA pneumonia since its activity is inhibited by pulmonary surfactant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/55,60\">",
"     55,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"     Daptomycin",
"    </a>",
"    has activity against MRSA, as well as against other resistant gram-positive bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/54,55,61\">",
"     54,55,61",
"    </a>",
"    ], and has been effective in animal models of MRSA infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/62\">",
"     62",
"    </a>",
"    ]. In a retrospective review from one institution, 16 children (median age 6.5 years) were treated with daptomycin for treatment of invasive gram-positive bacterial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/61\">",
"     61",
"    </a>",
"    ]: 15 had invasive staphylococcal disease, one with MSSA and 14 with MRSA (13 with CA-MRSA). Twelve of the children with disseminated staphylococcal infection had persistent bacteremia despite therapy with at least two drugs (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    , aminoglycoside,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    ); the addition of daptomycin resulted in bacteriologic cure in six of seven evaluable patients with persistent bacteremia. Daptomycin may be warranted in children with persistent bacteremia (&ge;4 days) in the absence of pulmonary involvement. Daptomycin should not be coadministered with vancomycin due to concerns for daptomycin resistance being induced by vancomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. MRSA susceptibilities to daptomycin should be closely followed during treatment with daptomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"     daptomycin",
"    </a>",
"    for children with serious infections has yet to be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. However, a 9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    single daily dose results in area-under-the-concentration-time curve (AUC) values similar to AUC values associated with effective treatment in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is one of the drugs of choice for treating VISA (",
"    <a class=\"graphic graphic_table graphicRef69174 \" href=\"mobipreview.htm?35/57/36765\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'VISA infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is a possible consideration in very selected children with serious MRSA infections when susceptibility testing has indicated that the isolate is susceptible to TMP-SMX (",
"    <a class=\"graphic graphic_table graphicRef78349 \" href=\"mobipreview.htm?42/2/43053\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no studies of the efficacy of TMP-SMX in invasive MRSA infections in children, although it has been effective in treating MSSA infections in children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In a randomized trial comparing TMP-SMX and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    for the treatment of serious",
"    <em>",
"     S. aureus",
"    </em>",
"    infections in intravenous drug users, TMP-SMX was less effective than vancomycin; nonetheless, it resulted in bacteriologic cure in 86 percent of patients with MRSA (compared to 98 percent with vancomycin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigational therapies for MRSA including glycopeptide agents, lysostaphin, ceftobiprole, and immunotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\", section on 'Investigational agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials evaluating antimicrobial agents for invasive methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) infections in children are lacking. The treatment approach suggested below is based on case series, in vitro susceptibility testing, and the clinical experience of experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,8,72\">",
"     4,8,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    alone or in combination with other drugs is the treatment of choice for severe MRSA infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Alternative agents, many of which are relatively new and poorly studied in children, may be considered in the setting of adverse effects to vancomycin&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef78349 \" href=\"mobipreview.htm?42/2/43053\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Given the limited number of antimicrobial agents with activity against MRSA and the increasing emergence of multidrug-resistant strains, treatment of suspected invasive MRSA infection in children is guided by a number of general principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specimens for culture and antimicrobial testing should be collected whenever possible before initiation of antimicrobial therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/5,8\">",
"       5,8",
"      </a>",
"      ]. Aspiration or surgical incision and drainage of bone or joint infections should be performed within 48 hours of starting antibiotic treatment.",
"     </li>",
"     <li>",
"      Quantitative antimicrobial susceptibility testing (to beta-lactam antibiotics,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      [TMP-SMX], tetracyclines,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"       daptomycin",
"      </a>",
"      ) and testing for clindamycin-inducible resistance should be performed for all staphylococci isolated from normally sterile sites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,22,73\">",
"       4,22,73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Final therapy decisions should be based upon results of cultures and susceptibility testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decisions regarding antimicrobial combinations should be individualized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/8\">",
"       8",
"      </a>",
"      ]. There are no data from controlled trials establishing a benefit for combination therapy. Antimicrobial combinations possibly increase bactericidal activity and prevent the emergence of antimicrobial resistance during therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      may be used as adjunctive agents but should not be used as single-drug therapy. Gentamicin may be associated with greater nephrotoxity.",
"     </li>",
"     <li>",
"      Potential foci of infection (eg, intravascular catheters, purulent collections) should be removed or drained [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/72,76,77\">",
"       72,76,77",
"      </a>",
"      ]. Imaging studies may be necessary to identify foci of infection that require drainage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/72\">",
"       72",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Microbiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consultation with an expert in infectious diseases is suggested for children with serious or life-threatening invasive infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/5,72\">",
"       5,72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EMPIRIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with invasive staphylococcal infections should be hospitalized and treated, at least initially, with intravenous (IV) antimicrobial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most healthcare-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (HA-MRSA) strains are multidrug resistant; most community-associated MRSA (CA-MRSA) strains are relatively susceptible to nonbeta-lactam antibiotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. However, there is variability among CA-MRSA strains. Some are resistant to multiple drugs and some have susceptibility patterns similar to HA-MRSA isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/3,21,23,82,83\">",
"     3,21,23,82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following factors should be considered when choosing empiric antimicrobial therapy for suspected staphylococcal infections in children (",
"    <a class=\"graphic graphic_table graphicRef61437 \" href=\"mobipreview.htm?23/38/24173\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,8,84\">",
"     4,8,84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severity and site of infection.",
"     </li>",
"     <li>",
"      History or risk of HA-MRSA acquisition; the isolates from children with identifiable risk factors for HA-MRSA are more likely to be resistant to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      than isolates from children without risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevalence of MRSA in the community; empiric antibiotics should include coverage for MRSA if the proportion of",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates is greater than 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibiotic susceptibility of MRSA in the community; the rates vary from community to community [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/1,3,83,85,86\">",
"       1,3,83,85,86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     For critically ill",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with life-threatening infections (eg, septicemia, endocarditis, overwhelming pneumonia, central nervous system infections, infections requiring admission to the intensive care unit) possibly due to",
"    <em>",
"     S. aureus",
"    </em>",
"    , we suggest empiric therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    ;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    may be added for potential synergy (",
"    <a class=\"graphic graphic_table graphicRef61437 \" href=\"mobipreview.htm?23/38/24173\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,22,74,84\">",
"     4,22,74,84",
"    </a>",
"    ]. The combination of vancomycin plus nafcillin or oxacillin is recommended to maximize coverage for both MRSA and methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    (MSSA). Additional antibiotics may be required for empiric treatment of non-staphylococcal pathogens until the pathogen is identified. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Vancomycin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Single-drug therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    is an alternative for children with pneumonia and without endovascular infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,8,72,87\">",
"     4,8,72,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     For serious infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antimicrobial therapy for children with nonlife-threatening serious infections (eg, osteomyelitis, septic arthritis, pneumonia with empyema) possibly due to",
"    <em>",
"     S. aureus",
"    </em>",
"    depends upon the prevalence of MRSA infection in the community and whether the patient has risk factors for HA-MRSA (",
"    <a class=\"graphic graphic_table graphicRef61437 \" href=\"mobipreview.htm?23/38/24173\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,8,72\">",
"     4,8,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In communities where the prevalence of MRSA infection is low (eg, &lt;10 percent),",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      may be used for empiric therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In communities where the prevalence of MRSA infection is high (eg, &gt;10 percent) and the prevalence of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      resistance is low (eg, &lt;10 percent), clindamycin may be used for empiric therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,22\">",
"       4,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For children with risk factors for HA-MRSA infection, empiric therapy should include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37159?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antimicrobial therapy for children with osteomyelitis in communities with a high prevalence of CA-MRSA (ie, &gt;10 percent) usually includes",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Children in communities with a high prevalence of clindamycin resistance should receive vancomycin pending results of susceptibility testing and D-test results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Empiric antimicrobial therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17495?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of antibacterial susceptibility testing\", section on 'D test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric treatment for suspected staphylococcal pneumonia in children should include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    if the child is critically ill.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is an alternative for children who are not critically ill and if the prevalence of clindamycin resistance in the community is low.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    is another option. General aspects of treatment of pneumonia in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27369?source=see_link&amp;anchor=H3#H3\">",
"     \"Outpatient treatment of community-acquired pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27882?source=see_link\">",
"     \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Skin and soft tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of suspected MRSA skin and soft-tissue infections is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33290?source=see_link\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DEFINITIVE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     MRSA infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin resistance in",
"    <em>",
"     S. aureus",
"    </em>",
"    is defined as an",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    minimum inhibitory concentration (MIC) &ge;4",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Isolates resistant to oxacillin or methicillin also are resistant to all beta-lactam agents, including cephalosporins (with the exception of ceftobiprole). Definitive therapy for invasive methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) infections depends upon results of susceptibility testing and the D test (",
"    <a class=\"graphic graphic_table graphicRef57379 \" href=\"mobipreview.htm?43/17/44316\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America, American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists recommend trough",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    concentrations between 15 and 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for adults with serious MRSA infections (eg, bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, necrotizing fasciitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/8,88,89\">",
"     8,88,89",
"    </a>",
"    ]. Whether higher vancomycin trough levels are necessary or safe in children is not yet known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. A reasonable approach for treating the child with invasive infection in the intensive care unit is to try to achieve vancomycin trough levels between 15 and 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    until blood cultures are sterile and the child is clearly improving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/8\">",
"     8",
"    </a>",
"    ]. At that point the dose of vancomycin could be decreased to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Doses greater than 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day are likely required to reach trough levels of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     VISA infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    -intermediate",
"    <em>",
"     S. aureus",
"    </em>",
"    (VISA) is defined as a vancomycin MIC 4 to 8",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Optimal therapy for VISA infections in children has yet to be determined. The choice of antibiotics depends upon the results of in vitro susceptibility studies (",
"    <a class=\"graphic graphic_table graphicRef69174 \" href=\"mobipreview.htm?35/57/36765\">",
"     table 2",
"    </a>",
"    ). Consultation with an expert in pediatric infectious diseases is suggested in the management of children with VISA infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VISA strains have variable susceptibility patterns, with some still susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. VISA strains also show in vitro susceptibility to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"     daptomycin",
"    </a>",
"    , but clinical experience with daptomycin in children is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/61,98\">",
"     61,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial case reported from Japan was treated with surgical debridement and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/3/29750?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    plus an aminoglycoside [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/95\">",
"     95",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    have been effective therapy for some VISA strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/52,99,100\">",
"     52,99,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     VRSA infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    -resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (VRSA) is defined as a vancomycin MIC &ge;16",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. VRSA strains have been susceptible to several other agents, including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1205?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"     daptomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/52,99,101,102\">",
"     52,99,101,102",
"    </a>",
"    ]. Consultation with an expert in pediatric infectious diseases is suggested in the management of children with VRSA infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy for invasive MRSA infection depends upon the site, but usually is at least four weeks for endocarditis, osteomyelitis, necrotizing pneumonia, or disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ]. Parenteral therapy is recommended for the entire course in patients with endocarditis and central nervous system infections. Oral therapy may be used for a portion of the course in patients with other types of infection provided that adherence to therapy can be ensured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TREATMENT OF NEONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Diseases Society of America provides guidance for the management of invasive methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) infections in infants (&le;28 days of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/8\">",
"     8",
"    </a>",
"    ]. The guidelines are based upon observations from a single-institution review of 126 cases treated between 2001 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend hospital admission for infants &le;28 days who have been evaluated for invasive infection (ie, infections extending beyond the skin and soft tissues) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=see_link\">",
"     \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric antimicrobial therapy should be based upon the local susceptibility pattern of community-associated",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates. The author's institution uses",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    for neonates with suspected invasive staphylococcal infection (",
"    <a class=\"graphic graphic_table graphicRef64140 \" href=\"mobipreview.htm?0/22/365\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When MRSA infection has been confirmed, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/8\">",
"     8",
"    </a>",
"    ];",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    are alternatives for nonendovascular MRSA infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/37,104\">",
"     37,104",
"    </a>",
"    ]. Linezolid should be used in consultation with an expert in infectious diseases.",
"   </p>",
"   <p>",
"    Neonates with invasive infection should complete antimicrobial therapy intravenously. General aspects of management of invasive infections in neonates are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16121?source=see_link\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/59/14264?source=see_link\">",
"     \"Urinary tract infections in newborns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=see_link\">",
"     \"Neonatal pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with invasive infections fail to respond to treatment with an agent to which their isolate is susceptible in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/72\">",
"     72",
"    </a>",
"    ]. Potential reasons for this include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced concentration at the site of infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/105-107\">",
"       105-107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heteroresistance to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      (eg, subpopulations of organisms with reduced susceptibility). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17495?source=see_link&amp;anchor=H10046302#H10046302\">",
"       \"Overview of antibacterial susceptibility testing\", section on 'Heteroresistance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strategies to overcome these problems include the addition of adjunctive antimicrobial agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/75\">",
"     75",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a change in antimicrobial therapy. In either case, consultation with an expert in pediatric infectious diseases is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/6/29802/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/4/22595?source=see_link\">",
"       \"Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of invasive methicillin-resistant",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      (MRSA) infection is guided by quantitative antimicrobial susceptibility testing; we recommend that such testing be performed on all staphylococci isolated from normally sterile sites. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive treatment requires removal or drainage of potential foci of infection (eg, intravascular catheters, purulent collections). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with suspected staphylococcal infections that are life threatening, we suggest empiric therapy with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      );",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      may be added for synergy (",
"      <a class=\"graphic graphic_table graphicRef61437 \" href=\"mobipreview.htm?23/38/24173\">",
"       table 4",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       Linezolid",
"      </a>",
"      is an alternative for patients with pneumonia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'For critically ill'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Vancomycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with nonlife-threatening but serious infections possibly caused by",
"      <em>",
"       S. aureus",
"      </em>",
"      , empiric therapy depends upon the prevalence of MRSA in the community and whether the child has risk factors for healthcare-associated (HA-) MRSA (",
"      <a class=\"graphic graphic_table graphicRef61437 \" href=\"mobipreview.htm?23/38/24173\">",
"       table 4",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the prevalence of MRSA infection is &lt;10 percent, we suggest empiric therapy with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the prevalence of MRSA infection is &gt;10 percent and the prevalence of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      resistance is &lt;10 percent, we suggest empiric therapy with clindamycin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the child has risk factors for HA-MRSA infection, we suggest empiric therapy with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H14\">",
"       'For serious infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Vancomycin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Clindamycin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend hospital admission for infants &le;28 days who have been evaluated for invasive infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment of neonates'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/38/40550?source=see_link&amp;anchor=H6#H6\">",
"       \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\", section on 'Limitations in neonates'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Empiric antimicrobial therapy for neonates with suspected invasive staphylococcal infection is based upon the local susceptibility pattern of community-associated",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      is one potential regimen;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"      is an alternative. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment of neonates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/1\">",
"      Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/2\">",
"      Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005; 159:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/3\">",
"      Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Staphylococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.653.",
"    </li>",
"    <li>",
"     Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf (Accessed on September 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/6\">",
"      Choice of antibacterial drugs. Treat Guidel Med Lett 2007; 5:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/7\">",
"      Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/8\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/9\">",
"      Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/10\">",
"      Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/11\">",
"      Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/12\">",
"      Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/13\">",
"      Gonz&aacute;lez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/14\">",
"      Mason EO, Lamberth LB, Hammerman WA, et al. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol 2009; 47:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/15\">",
"      Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/16\">",
"      Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/17\">",
"      Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/18\">",
"      Mart&iacute;nez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/19\">",
"      Mart&iacute;nez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/20\">",
"      Szczesiul JM, Shermock KM, Murtaza UI, Siberry GK. No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections. Pediatr Infect Dis J 2007; 26:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/21\">",
"      Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/22\">",
"      Kaplan SL. Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005; 24:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/23\">",
"      Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/24\">",
"      Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis. Clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976; 60:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/25\">",
"      Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J 2006; 25:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/26\">",
"      Hult&eacute;n KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J 2006; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/27\">",
"      Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003; 41:4740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/28\">",
"      Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 1999; 44:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/29\">",
"      Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.",
"     </a>",
"    </li>",
"    <li>",
"     Zyvox&reg; (Linezolid) package insert. Pfizer, NY, NY 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/31\">",
"      Chen CJ, Chiu CH, Lin TY, et al. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007; 26:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/32\">",
"      Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/33\">",
"      Ben Mansour EH, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003; 22:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/34\">",
"      Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005; 37:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/35\">",
"      Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002; 35:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/36\">",
"      Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006; 27:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/37\">",
"      Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003; 22:S158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/38\">",
"      Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2003; 22:S178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/39\">",
"      Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/40\">",
"      S&aacute;nchez Garc&iacute;a M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/41\">",
"      Lyseng-Williamson KA, Goa KL. Linezolid: in infants and children with severe Gram-positive infections. Paediatr Drugs 2003; 5:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/42\">",
"      Saiman L, Goldfarb J, Kaplan SA, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003; 22:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/43\">",
"      Meissner HC, Townsend T, Wenman W, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/44\">",
"      Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/45\">",
"      Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 2009; 28:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/46\">",
"      Nambiar S, Rellosa N, Wassel RT, et al. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics 2011; 127:e1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/47\">",
"      Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/48\">",
"      Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/49\">",
"      Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol 2001; 39:3586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/50\">",
"      Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/51\">",
"      Vouillamoz J, Entenza JM, F&eacute;ger C, et al. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 2000; 44:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/52\">",
"      Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/53\">",
"      Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002; 21:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/54\">",
"      Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/55\">",
"      Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/56\">",
"      Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/57\">",
"      Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.",
"     </a>",
"    </li>",
"    <li>",
"     Cubist Cubicin marketing to highlight single daily dose of antibiotic. In: \"The Pink Sheet\" F-D-C Reports, Chevy Chase, MD, September 22, 2003. p.22.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/59\">",
"      Daptomycin (Cubicin) for skin and soft tissue infections. Med Lett Drugs Ther 2004; 46:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/60\">",
"      Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/61\">",
"      Ardura MI, Mej&iacute;as A, Katz KS, et al. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J 2007; 26:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/62\">",
"      Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/63\">",
"      Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/64\">",
"      Jacobson LM, Milstone AM, Zenilman J, et al. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2009; 28:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/65\">",
"      Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008; 27:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/66\">",
"      Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2011; 30:712.",
"     </a>",
"    </li>",
"    <li>",
"     Chandorkar G, Abdel-Rahman S, Jacobs R, et al. Pharmacokinetics (PK) and safety of 8 and 10 mg/kg of daptomycin in pediatric patients aged 2 to 6 years (abstract 1243). Data presented October 31, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/68\">",
"      Ardati KO, Thirumoorthi MC, Dajani AS. Intravenous trimethoprim-sulfamethoxazole in the treatment of serious infections in children. J Pediatr 1979; 95:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/69\">",
"      Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004; 38:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/70\">",
"      Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004; 50:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/71\">",
"      Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/72\">",
"      Fergie J, Purcell K. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2008; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/73\">",
"      Jimenez-Truque N, Thomsen I, Saye E, Creech CB. Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children? Pediatr Infect Dis J 2010; 29:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/74\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/75\">",
"      Tan TQ, Mason EO Jr, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993; 37:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/76\">",
"      Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 43:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/77\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/78\">",
"      Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/79\">",
"      Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/80\">",
"      Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis J 2001; 20:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/81\">",
"      Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999; 18:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/82\">",
"      Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/83\">",
"      Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002; 43:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/84\">",
"      Paintsil E. Pediatric community-acquired methicillin-resistant Staphylococcus aureus infection and colonization: trends and management. Curr Opin Pediatr 2007; 19:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/85\">",
"      Braun L, Craft D, Williams R, et al. Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J 2005; 24:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/86\">",
"      Dietrich DW, Auld DB, Mermel LA. Community-acquired methicillin-resistant Staphylococcus aureus in southern New England children. Pediatrics 2004; 113:e347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/87\">",
"      Kaplan SL. Implications of methicillin-resistant Staphylococcus aureus as a community-acquired pathogen in pediatric patients. Infect Dis Clin North Am 2005; 19:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/88\">",
"      Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/89\">",
"      Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/90\">",
"      McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/91\">",
"      Moffett BS, Kim S, Edwards M. Vancomycin nephrotoxicity may be overstated. J Pediatr 2011; 158:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/92\">",
"      Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009; 28:398.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute (CLSI)/National Committee for Clinical Laboratory Standards (NCCLS). 2006. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. NCCLS document M100-S16. National Committee for Clinical Laboratory Standards, Wayne, PA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/94\">",
"      Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/95\">",
"      Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/96\">",
"      Centers for Disease Control and Prevention (CDC). Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/97\">",
"      Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/98\">",
"      Jevitt LA, Smith AJ, Williams PP, et al. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist 2003; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/99\">",
"      Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/100\">",
"      Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/101\">",
"      Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003; 47:3960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/102\">",
"      Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/103\">",
"      Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/104\">",
"      Bradley J, Frenck R. CA-MRSA infections an increasing concern in early infancy. AAP News 2006; 27:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/105\">",
"      Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/106\">",
"      Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/6/29802/abstract/107\">",
"      Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6057 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29802=[""].join("\n");
var outline_f29_6_29802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIMICROBIAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vancomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clindamycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Inducible resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Linezolid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Quinupristin-dalfopristin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Daptomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      For critically ill",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      For serious infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Skin and soft tissue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DEFINITIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MRSA infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      VISA infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      VRSA infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TREATMENT OF NEONATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6057|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/31/31217\" title=\"picture 1\">",
"      MRSA susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6057|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/2/43053\" title=\"table 1\">",
"      Rx serious MRSA child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/57/36765\" title=\"table 2\">",
"      Rx serious VISA child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/17/44316\" title=\"table 3\">",
"      Rx serious MSSA child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/38/24173\" title=\"table 4\">",
"      Empiric rx serious SA child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/60/3020\" title=\"table 5\">",
"      Rx MRSA skin infections in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/22/365\" title=\"table 6\">",
"      Neonatal doses MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27882?source=related_link\">",
"      Management and prognosis of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27369?source=related_link\">",
"      Outpatient treatment of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/4/22595?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/38/40550?source=related_link\">",
"      Strategies for the evaluation of fever in neonates and infants (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37159?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/59/14264?source=related_link\">",
"      Urinary tract infections in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16425?source=related_link\">",
"      Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_6_29803="Beighton Score for joint laxity";
var content_f29_6_29803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Beighton score for joint laxity*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Specific joint laxity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Left",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Right",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Passive apposition of thumb to forearm",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Passive hyperextension of fingers",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active hyperextension of elbow &gt;10 degress",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active hyperextension of knee &gt;10 degrees",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to flex spine and place palms to floor without bending knees",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This score is based upon joint laxity of the above nine anatomic sites. It is calculated by adding all points, with nine being the highest total possible score. A score of four or higher is generally considered an indication of generalized joint laxity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29803=[""].join("\n");
var outline_f29_6_29803=null;
var title_f29_6_29804="DSM IV criteria autism";
var content_f29_6_29804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for autistic disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A. A total of six or more items from 1., 2., and 3., with at least two from 1., and one each from 2. and 3.:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Qualitative impairment in social interaction, as manifested by at least two of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Marked impairment in the use of multiple nonverbal behaviors such as eye-to-eye gaze, facial expression, body posture, and gestures to regulate social interaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Failure to develop peer relationships appropriate to developmental level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. A lack of spontaneous seeking to share enjoyment, interests, or achievements with other people (eg, by a lack of showing, bringing, or pointing out objects of interest)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        d. Lack of social or emotional reciprocity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Qualitative impairments in communication as manifested by at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Delay in, or total lack of, the development of spoken language (not accompanied by an attempt to compensate through alternative modes of communication such as gesture or mime)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. In individuals with adequate speech, marked impairment in the ability to initiate or sustain conversation with others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. Stereotyped and repetitive use of language or idiosyncratic language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        d. Lack of varied, spontaneous make-believe play or social imitative play appropriate to developmental level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Restricted repetitive and stereotyped patterns of behavior, interests, and activities, as manifested by at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Encompassing preoccupation with one or more stereotyped and restricted patterns of interest that are abnormal either in intensity or focus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Apparently inflexible adherence to specific, nonfunctional routines or rituals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. Stereotyped and repetitive motor mannerisms (eg, hand or finger flapping or twisting, or complex whole-body movements)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        d. Persistent preoccupation with parts of objects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Delays or abnormal functioning in at least one of the following areas, with onset prior to age three years: 1. social interaction, 2. language as used in social communication, or 3. symbolic or imaginative play",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. The disturbance is not better accounted for by Rett disorder or childhood disintegrative disorder (CDD)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29804=[""].join("\n");
var outline_f29_6_29804=null;
var title_f29_6_29805="Hyponatremia in HF";
var content_f29_6_29805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyponatremia associated with reduced survival in patients with severe chronic heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 243px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival over time in patients with severe chronic heart failure and a left ventricular ejection fraction less than 30 percent who, at study entry, had either a normal plasma sodium concentration (greater than 137 meq/L, solid line) or hyponatremia (plasma sodium less than or equal to 137 meq/L, dashed line). Survival was significantly reduced in the patients with hyponatremia. The survival rate was very low (approximately 15 percent at 12 months) in those with a baseline plasma sodium concentration less than or equal to 130 meq/L.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lee WH, Packer M. Circulation 1986; 73:257.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29805=[""].join("\n");
var outline_f29_6_29805=null;
var title_f29_6_29806="Nasolacrimal duct obstruction";
var content_f29_6_29806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasolacrimal duct obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 150px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Infants with nasolacrimal duct obstruction present with a history of chronic or intermittent tearing, debris on the eyelashes, and sometimes redness of the conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Paysse EA, Coats DK, Cassidy M. Refinements Volume III/Number 2. San Francisco: American Academy of Opthalmology, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29806=[""].join("\n");
var outline_f29_6_29806=null;
var title_f29_6_29807="Gram stain peritoneal answer";
var content_f29_6_29807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mixed flora from a ruptured viscus: Gram stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of peritoneal fluid (x1000) shows several different organisms, including Gram positive cocci in chains, Gram positive rods, plump enteric Gram negative bacilli, and thinner Gram negative rods. Mixed fecal flora grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_6_29807=[""].join("\n");
var outline_f29_6_29807=null;
